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ABSTRACT  
                       Development of nanotechnology-based drug delivery and imaging systems to the 
white adipose tissue vasculature using a Wistar rat model 
 
N. Thovhogi 
 
PhD thesis, Department of Biotechnology, Faculty of Science, University of the 
Western Cape 
 
Obesity is a complex metabolic disease of excessive fat accumulation. It is a 
worldwide epidemic affecting billions of people and its pharmacological management 
is hampered by drug toxicity and undesirable side effects. Therefore, a need still 
exists for the development of safe medication for treatment of obesity. 
Nanotechnology involves the use of small particles at atomic and molecular scale. It 
has application in medical diagnostics, drug delivery and molecular imaging. Various 
nanoparticles (NPs) functionalized with different biomolecules have been successfully 
used in many therapeutic and research applications due to their versatility, ease of 
chemical synthesis, low toxicity and unique properties. Examples of NPs used in this 
study are Gold nanoparticles (GNPs) and Quantum dots (QDs). GNPs and QDs are 
extensively used as drug delivery, labelling and imaging tools in biomedical research. 
 
 Nanotechnology offers a new potential useful avenue for solving the problem of 
toxicity of anti-obesity drugs. This could be achieved through targeted drug delivery. 
In this study, rats were fed a high fed diet (HFD) to induce obesity. The streptavidin 
conjugated GNPs and QDs were functionalized with biotinylated adipose-homing 
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peptide (AHP) and/or anti-obesity drug (Gallic acid). Functionalization was 
characterized using agarose gel electrophoresis, UV-vis spectroscopy and 
transmission electron microscopy. The binding-specificity and targeting ability of 
AHP was evaluated in vitro and in vivo. The apoptotic effect of AHP functionalized-
drug loaded GNPs (AHP-GA-GNPs) was tested in vitro using APOPercentage 
TM
 and 
Caspase-3 activation assays.  
 
The in vitro data indicated that the binding was specific to prohibitin (PHB) 
expressing cells (MCF-7 and Caco-2), and that the binding was temperature 
dependent. PHB was confirmed as a target for AHP after overlaying AHP-FITC and 
anti-prohibitin antibody staining. Cellular uptake was detected on the cells treated 
with AHP-functionalized NPs as compared to unfunctionalized NPs. The GA and 
AHP-GA-GNPs reduced cellular viability and induced apoptosis through activation of 
Caspase-3. The Ex-vivo studies using primary endothelial cells (ECs) isolated from 
the WAT of lean and obese Wistar rats showed that the binding of AHP was receptor 
mediated, and specific to receptors differentially expressed in ECs from obese WAT.  
 
The in vivo studies showed that, treatment of obese rats with AHP-functionalized NPs 
resulted in targeted delivery of the NPs to the WAT as compared to those treated with 
unfunctionalized NPs. Qualitative analysis using fluorescence microscopy and IVIS 
Luminar XR, live-imaging system showed that the unfunctionalized NPs accumulated 
mostly in the organs of the reticuloendothelial system, namely: liver, spleen, lungs 
and kidneys. In contrast, AHP-functionalized NPs accumulated mostly in the WATs 
as compared to the rest of the organs of the obese rats. Uptake and binding of the NPs 
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to the tissues was quantitatively confirmed by the inductive coupled plasma-optical 
emission spectroscopy (ICP-OES).  
 
In conclusion, this study reports the 1) successful functionalization of GNPs and QDs 
with AHP, 2) use of AHP-functionalized GNPs and QDs as delivery and imaging 
agents to the WAT, and 3) potential use of AHP-functionalized drug-loaded GNPs in 
the treatment of obesity.  
 
KEYWORDS: 
 
Obesity; White adipose tissue; Nanotechnology; Drug delivery; Targeting peptides;  
Live imaging; Gold nanoparticles; Quantum dots; Gallic acid; Anti-obesity.                                             
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CHAPTER 1 
 
1. Literature review 
1.1 Obesity 
 
Obesity is a complex metabolic disease of excessive fat accumulation in adipose 
tissue (Belsing and Rasmussen, 2004; Kissler and Settmacher, 2013). It is a 
worldwide epidemic affecting billions of people and now recognized as a major 
public health problem in industrialized as well as in developing countries (Langin, 
2006; Kissler and Settmacher, 2013). It occurs through a long-standing imbalance 
between energy intake and energy expenditure, which leads to the excess 
accumulation of fat in various adipose tissues and organs (Belsing and Rasmussen, 
2004; Bertolini et al., 2012). 
 
1.2. Causes and prevalence of obesity 
 
Obesity is caused by the accumulation of adipose tissue to excess and to an extent that 
impairs both physical and psychosocial health. It is characterized by increased storage 
of fatty acids in an expanded adipose tissue mass (Galic et al., 2009). Obesity is 
caused by either genetic or environmental factors (Dubnov et al., 2003; Loos and 
Bouchard, 2003; Phan-Hug et al., 2012). The environmental factors include 
consumption of high fat diets, lack of physical exercise, and psychological factors. To 
date, about 250 chromosome loci found on all but the Y chromosome are thought to 
influence the genetic predisposition for obesity (Dubnov et al., 2003). The growing 
prevalence of obesity is apparently not due to genetic changes, but rather to the 
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environmental effects acting on a genetic susceptibility. The obsession of getting 
„more for their money‟ leads consumers to increase food intake. The palatability of 
high fat foods leads to a higher caloric intake for the same portion size. These factors 
combine to increase total energy intake throughout the day, (Rosmond and Bjontore, 
2000; Dubnov et al., 2003; Lavie et al., 2009). Obesity is a major health problem in 
developed countries, and is rapidly becoming an important health problem in 
developing countries (Dizdar and Alyamac, 2004).  
 
In 2005, prevalence of obesity in developed countries, such as the United States, was 
as high as 26.6 % in men and 32.2 % in women above age 20 years (Goedecke et al., 
2005). In 2010, the World Health Organisation (WHO) showed that, 400 million 
adults were classified as obese and 1.6 billion as overweight worldwide (WHO, 
2010). The WHO, also predict that by 2015, approximately 2.3 billion adult will be 
overweight and more than 700 million will be obese (WHO, 2006). Presently, WHO 
projects that by 2025, 60 % of death worldwide will be caused by obesity related 
diseases (WHO, 2010). The prevalence of obesity among children, adolescents and 
adults has been dramatically increasing during the last decades. Thus, obesity is 
acquiring the characteristics of an authentic pandemia and it has been recognized as 
one of the major global health problems (Mokdad et al., 2003 and Huxley et al., 
2010).  
 
Table 1.1 shows obesity epidemic in both adult males and female worldwide. 
Globally, women are generally more prone to becoming obese than men (WHO, 
2010). The prevalence of obesity (Body mass index (BMI) ≥ 30 kg/m2) and 
overweight (BMI = 25 – 29.9 kg/m2) has been increasing steadily since the past 
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decade in both males and females (Racette et al., 2003).  It was estimated in 2010, 
that the prevalence of obesity for adults (>15 years) was higher in the USA for males 
and females with 44.2 % and 48.3 %, respectively. However, obesity is not only a 
problem of developed countries but is becoming an increasing problem in countries 
undergoing epidemiological transition, such as South Africa, Mexico and South 
American countries (Goedecke et al., 2005). In South Africa, 68.5 %  and 36.8 % of 
women were considered overweight and obese, while 39.3 % and 7.6 % of men were 
overweight and obese respectively (WHO, 2010). However, obesity and its co-
morbidities negatively affect the lives of many South Africans and the consequent 
burden of disease contributes to the increasing cost of health care, both at a state level 
and in the private sector (Goedecke et al., 2005). 
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Table 1.1. Obesity rates among adults and epidemiology of obesity worldwide.  
The OECD Health Data 2011; (http://dx.doi.org/10.1787/888932523956)    
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1.3. Measurement of obesity 
 
Measures of central adiposity, namely waist circumference (WC), waist-to-hip ratio 
(WHpR), a newly described index and a waist to- height ratio (WHR), have been 
adopted as more accurate predictors of obesity-related cardiovascular risk and have 
replaced Body mass index (BMI) in several ways for clinical diagnosis of metabolic 
syndrome (Lavie et al., 2009; Sahin et al., 2011). 
 
1.3.1. Body mass index (BMI) 
 
Obesity is a result of excess body fat. A simple and useful measure to define obesity 
is the ratio of weight and height squared (kg/m
2
) known as the BMI (Lavie et al., 
2009). Presently, approximately 2.8 million adult deaths are associated with 
pathological BMI increase, bringing excess obesity to the fifth leading life threat. The 
BMI is the indicator most commonly used for determining obesity. It is used to define 
severity of overweight and obesity across populations. A BMI can be categorized as 
underweight (≤18.5 kg/m2), normal weight (18.5 to 24.9 kg/m2), overweight (25 to 
29.9 kg/m
2
), obese (30 to 34.9 kg/m
2
), or severely obese (>35 kg/m
2
) (Formiguera and 
Canton, 2004; Leitzmann et al., 2006; Lavie et al., 2009; Kissler and Settmacher, 
2013)  
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Table 1.2. Classification of BMI 
 (Formiguera and Canton, 2004; Leitzmann et al., 2006) 
 
BMI range – kg/m2 Classification Health Risk 
 
<18.5 
 
Underweight 
 
Risk of developing problems such as nutritional 
deficiency and osteoporosis 
18.5 -24.9 Normal Low Risk (healthy range) 
29-29.9 Overweight Moderate risk of developing heart disease, high 
blood pressure, stroke, diabetes 
>30.0-34.9 Obesity I High risk of developing heart disease, high 
blood pressure, stroke, diabetes 
35-39.9 Obesity 11 High risk of developing heart disease, high 
blood pressure, stroke, diabetes 
>40 Extreme obesity High risk of developing heart disease, high 
blood pressure, stroke, diabetes 
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1.3.2. The waist circumference 
There are two main types of obesity regarding the fat distribution pattern: Android or 
central obesity, with the majority of fat depots located in the abdominal area, thus 
both subcutaneous and visceral, and Gynoid or peripheral obesity where the fat 
depots are mainly located subcutaneously in the lower body (hips and lower 
extremities). The difference between both types is fundamental, because the metabolic 
and cardiovascular complications of obesity are almost exclusively related to visceral 
fat depots. Because of its high correlation with visceral adipose tissue (Despres et al., 
2001; Sahin et al., 2011), a measure as simple as the waist circumference is a good 
way to assess cardiovascular risk. A waist girth over 88 cm for women and above 102 
cm for men indicates a high cardiovascular risk (Formiguera and Canton, 2004). 
1.3.3. The waist-to-hip ratio (WHpR) 
The WHpR is still a useful measure to be considered in obesity evaluation (Lavie et 
al, 2009), although its use has decrease during the last five or seven years as a 
measure of fat distribution. In patients with severe and very severe forms of obesity 
(class II and III obesities), with waist circumferences clearly beyond the upper risk 
limits, the WHpR is the best way to evaluate the fat distribution pattern, (Formiguera 
and Canton, 2004; Kissler and Settmacher, 2013) 
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1.4. Obesity as a health risk factor of other diseases 
 
Unhealthy diet and physical inactivity can contribute to many chronic diseases and 
conditions. The increases in overweight and obesity in adults are widely projected to 
continue to heighten the burden of obesity-related morbidity and mortality in the 
coming decades (Swinburn et al., 2011). Obesity is associated with hyperinsulinemia, 
insulin resistance and abnormalities in lipid metabolism (Konyanda et al., 1997; Kahn 
and Flier, 2000; Qatanani and Lazar, 2007; Lavie et al., 2009).  
 
As shown in Figure 1.1, obesity is strongly associated with a number of chronic 
diseases: hyperlipidemia, hypertension, diabetes (type 2 diabetes), coronary 
atherosclerotic heart disease, gout, restrictive lung disease, gall bladder disease, 
cancer, degenerative arthritis, infertility and cancer which includes uterine, breast, 
gallbladder, colon and prostate cancer, (Sidik and Ahmad, 2004). It is also associated 
with metabolic abnormalities such as impaired glucose tolerance, dyslipidaemia with 
elevated triglyceride levels, decreased high-density lipoprotein (HDL), cholesterol 
concentration and increased proportion of small dense lipoparticles (Prieto-Hontoria 
et al., 2011). Therefore, health consequences of obesity are huge and varied, ranging 
from an increased risk of premature death to several non-fatal but debilitating diseases 
that have adverse effects on quality of life (Lavie et al., 2009; Prieto-Hontoria et al., 
2011). 
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Figure 1.1. Schematic representation for obesity complications. 
The figure shows obesity as a health risk factor for chronic disease of lifestyle (http://health-care-
org.blogspot.com/2013/01/being-modest-obese-might-not-present.html) 
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1.5. Management of obesity 
 
Obesity cannot be cured, but only managed (Dubnov et al., 2003). The conventional 
management of obesity includes lifestyle modification, pharmacotherapy (antiobesity 
drugs) and surgery. Management of obesity starts with comprehensive lifestyle 
management (i.e, healthy diet, physical activity and behavior modification) (Sidik and 
Ahmad, 2004; Phan-Hug et al., 2012). 
 
1.5.1. Behavioural changes, physical activity and healthy diet 
 
As obesity cannot be cured, there is a need for life-long changes in certain habits; 
behavior has a major role in the maintenance of the newly reduced body weight. The 
goal of changing everyday behavior is to reduce food intake and increase energy loss. 
A major cause for the weight gain is again lack of sufficient physical activity (Dubnov 
et al., 2003). Increased physical activity is therefore an important component of 
lifestyle modification (Donnelly et al.,2004) The type of exercise recommended for 
weight loss is aerobic, such as walking, jogging, swimming, cycling and aerobic 
dancing (Dubnov et al, 2003; Phan-Hug et al., 2012). Healthy diet and exercise is the 
most natural, but not always the easiest.  The food pyramid for healthy diet is 
indicated in Figure 1.2. 
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Figure 1.2. The food pyramid, for healthy diet. 
The figure represents the food guide pyramid for the recommended intake for each food group 
(http://sharnyandjulius.com/healthy-food-pyramid-is-making-you-fat/). 
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1.5.2. Pharmacological treatment  
 
When lifestyle interventions do not induce sufficient weight loss, it may be necessary 
to add a pharmacologic agent to the treatment regimen. However, it has been 
recommended that pharmacotherapy should not be initiated without concomitant 
lifestyle modifications. Anti-obesity medications as listed in Table 1.3, should be used 
as part of a comprehensive weight loss program that includes diet and physical 
activity for obese patients, and for those with a BMI >27 kg/m
2
 (Claphan et al., 2001). 
Several anti-obesity drugs have been marketed with mechanisms of action targeting 
various physiological processes including calorie absorption, appetite control, and 
metabolism (Bray and Greenway, 2007; Arkinson, 1997). Thus far, all have been 
associated with side-effects spanning from insomnia and depression to potentially 
lethal cardiotoxicity (Elangbam, 2009). As a result, many of these drugs have been 
withdrawn (dexfen-fluramine, sibutramine, rimonabant) or restricted in their 
applications.  
 
However, to date, the number of drugs approved for the treatment of obesity is very 
limited. Currently, there are virtually no truly effective anti-obesity drugs approved by 
Unites States Food and Drug Administration (FDA). Orlistat is a lipase inhibitor that 
has been demonstrated to reduce fat absorption in humans by an impressive 30 % 
(Bray and Greenway, 2007). Unfortunately, there are gastrointestinal side effects 
associated with Orlistat and weight loss of 5 % is only achieved by 15 – 30 % of 
patients. Phentermine functions by suppressing appetite, although 8 – 10 % weight 
loss has been observed with its use, it is ineffective for a period longer than three 
months (Sirin and Kolonin, 2012). Due to their side effects, both Orlistat and 
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Phentermine can only be used by a limited number of patients. Several other drugs 
against obesity and obesity- associated conditions are now being tested as individual 
agents or as dual-target treatments, such as Qnexa, the combination Phentermine and 
Topiramate (Sirin and Kolonin, 2012).  
 
A list of current key drug candidates, which changes intermittently, is shown in Table 
1.3, (Hossen et al., 2012; Sirin and Kolonin, 2012). Because of the problems 
associated with anti-obesity drugs, there is a need to develop better strategy which 
will be used in the treatment of obesity.  
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Table 1.3. A summary of current pharmacological approaches to obesity treatment. 
 (Sirin and Kolonin, 2012) 
Drug  Other names 
(manufacturer)  
FDA status  Indication 
 
Orlistat 
 
Alli 
(GlaxoSmithKline)  
Xenical (Roche)  
 
Approved 2007 
 Approved 1999  
 
Obesity 
Phentermine  Suprenza (Alpex 
Pharma)  
Approved 2011 Obesity 
Dexfenfluramine  Redux (Wyeth-Ayerst)  Approved 1996  
Withdrawn 1997  
Obesity 
Fenfluramine  Pondimin (Wyeth-
Ayerst)  
Approved 1973  
Withdrawn1997  
Obesity 
Rimonabant  Zimulti (Sanofi 
Aventis)  
Rejected 2007  Obesity 
Sibutramine  Meridia (Abbott)  Approved 1997  
Withdrawn 2010  
Obesity 
Pramlintide  Symlin (Amylin 
pharmaceuticals)  
Approved 2005 Diabetes 
Metformin  Glucophage (Bristol-
Myers Squibb)  
Approved 1995  Diabetes 
Pioglitazone (TZD)  Actos (Takeda 
Pharmaceuticals)  
Approved 1999  Diabetes 
Rosiglitazone (TZD)  Avandia (SB Pharmco)  Approved 1999  Diabetes 
Phentermine/Topiramate 
(combination)  
Qnexa (Vivus)  Pending  Obesity 
Adipotide  (Ablaris Therapeutics) Investigational 
new drug (IND) 
 
Obesity 
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1.5.3. Phenolics and gallic acid 
 
Plants are a well-known source of molecules with pharmacologic activity. A huge 
number of secondary metabolites of plant origin are now being investigated in pre-
clinical and clinical settings, in the treatment of diseases and also as potential anti-
tumour drugs (Pellegrina et al., 2005). Phenolics such as hydroxybenzoic acid and 
hydroxycinnamic acids are widespread in the vegetal kingdom and most of these 
molecules have anti-inflammatory and antioxidant properties (Tapiero et al., 2002; 
Pellegrina et al., 2005; Hsu and Yen, 2006). Other phenolics, such as gallic acid 
(GA), show selective cytotoxicity against a variety of tumour cells. These compounds 
may serve as anti-tumour drugs or as the molecular basis for the synthesis of new 
drugs by targeted chemical modifications (Pellegrina et al., 2005; Ho et al., 2010). 
 
The GA a 3,4,5-trihydroxybenzoic acid, is a type of phenolic acid and a naturally 
abundant compound found in gallnuts, tea leaves, oak bark, and other plants. It has a 
chemical formula of C6 H2 (OH) 3 COOH as indicated in Figure 1.3. GA is reported to 
have antioxidant, anti-mutagenic and anti-carcinogenic activity (Pellegrina et al., 
2005; Hsu and Yen, 2006; You et al., 2010) and is expected to reduce the risk of 
disease and brings health benefits through daily intake. Epidemiological evidence has 
shown that its dietary intake play a role in the prevention of several chronic diseases 
such as cancer, cardiovascular diseases (CVD) and diabetes (Hsu et al., 2006). A 
number of studies have demonstrated that antioxidants may modulate obesity in mice 
or rats fed high fat-diets (HFD) (Han et al., 2003; Hsu et al., 2006). Some in vitro 
studies indicated that GA has the highest inhibition of 3T3-L1 pre-adipocyte 
population growth among other phenolic acids tested (Hsu et al., 2006). Therefore, 
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the research on phenolic acids is of major interest due to their important biological 
and pharmacological properties.  
 
 
 
 
Figure 1.3. Representation for the structure of gallic acids 
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1.5.4. Bariatric surgery 
  
Surgical approaches to weight loss, such as bariatric surgery to inactivate parts of 
gastrointestinal tract have shown to be effective as a long-term weight loss 
intervention in morbidly obese patients (BMI ≥ 40kg/m2 (Kissler and Settmacher, 
2013). Bariatric surgery can be defined as surgery that modifies the gastrointestinal 
tract with the purpose of decreasing calorie absorption and therefore decreasing body 
weight (Buchwald et al., 2004; Kissler and Settmacher, 2013).  
 
It encompasses a range of surgical procedures that classified as either restrictive or 
malabsorptive. The restrictive procedure includes laparoscopic gastric banding 
(LAGB) and laparoscopic sleeve gastrectomy (LSG), both designed to decrease the 
quantity of food intake by reducing the available gastric volume. Malabsorptive 
bariatric procedures, which include Roux-en-Y gastric bypass (RYGB) and 
biliopancreatic diversion or duodenal switch (BPD-DS), are designed to decrease 
absorption of nutrients ingested. Restriction of calories or diet therapy reduces overall 
weight in the short term, however, unless coupled with a weight management strategy 
or program, are relatively ineffective at producing long-term weight loss (Buchwald et 
al., 2004; Gill et al., 2011). 
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1.6. Adipose tissue  
 
Adipose tissue (AT) is an innervated loose connective tissue, classically defined as a 
tissue mass that stores excess energy and provides insulation and padding to the body 
(Kershaw and Flier, 2004). It is composed of number of different cell types held 
together by matrix of collagen fibres. This includes mature fat cells (adipocytes) 
surrounded by a stromal vascular cell fraction containing  preadipocytes, endothelial 
cells, pericytes, fibroblasts, macrophages, monocytes and mesenchymal stem cells 
(Kershaw and Flier, 2004).  
 
The growth of AT involves both cellular hypertrophy and hyperplasia. Hypertrophy 
(increase in cell size) is due to excess triglyceride accumulation in the adipocyte and 
hyperplasia (increase in cell number) results from the recruitment of new adipocytes 
from precursor cells (preadipocytes) in AT. Hypertrophy usually preceeds 
hyperplasia. Expansion of adipose tissue can be supported by both neovascularization 
(for adipocyte hyperplasia) and dilation and remodeling of existing capillaries (for 
adipocyte hypertrophy). The development of hyperplastic adipose tissue is associated 
with the most severe forms of obesity and has the poorest prognosis for treatment. 
Proliferation of adipocytes is influenced by circulating factors, neuronal inputs, and 
autocrine/paracrine factors secreted by cells within the AT (Dizdar and Alyamak, 
2004). 
 
The AT secretes various pro-angiogenic substances and growth factors (Trayhurn and 
Beattie, 2001; Balwierz et al., 2008). It has been reported that human adipose tissue 
contains a population of non-characterized cells that are able to undergo adipogenic, 
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osteogenic, chondrogenic or miogenic differentiation in vitro.  Such cells, called 
stromal-vascular fraction (SVF) cells, can be used for repair of tendons and bone as 
well as skeletal muscle (Balwierz et al., 2008). Wosnitza and co-workers have shown, 
that adipose tissue also contains a population of CD31- as well as CD31+ cells, and 
both cell populations could be differentiated into adipocytes as well as endothelial 
cells; this could indicate a potential of trans differentiating endothelial cells to 
adipocytes (Wosnitza et al., 2007). 
 
The AT plays a crucial role in the regulation of whole-body fatty acid homeostasis 
(Galic et al., 2009). The functions of adipose tissue can be classified into three 
aspects. The first function is related to lipid metabolism including triglycerides (TGs) 
storage and fatty acids (FA) release. Second, it catabolizes TGs in order to release 
glycerol and FAs that participate in glucose metabolism in liver and other tissues. 
Finally, adipocytes secrete adipokines, which include hormones, cytokines and other 
proteins with specific biological functions (Morrison et al., 2000; Galic et al., 2009). 
For these reasons, adipose tissue has an important influence on physiological 
processes such as development and growth of the adipocyte and energy homeostasis. 
In addition, adipocytes and adipose tissue are actively involved in metabolic processes 
such as angiogenesis, adipogenesis, extracellular matrix dissolution and reformation, 
steroid metabolism, immune response and hemostasis (Bays et al., 2008).  
 
There are two main types of AT depending on the cell structure, location, colour, 
vascularization and function: brown adipose tissue and white adipose tissue. 
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1.6.1. Brown adipose tissue (BAT) 
 
The BAT also known as “brown fat” are specialized thermogenic adipose tissue used 
for thermoregulation and cold defence of small mammals (Kershaw and Flier, 2004). 
It is mainly responsible for energy metabolism, and its function requires efficient 
blood perfusion to supply nutrients and oxygen and to export heat. BAT contains 
multilocular adipocytes. It has a large number of mitochondria and is specialized in 
heat production and energy expenditure. Research interest in brown fat has risen 
greatly upon the discovery that in certain animal models increased BAT 
thermogenesis can be a means of dissipating excess energy and thus preventing 
obesity (Cypess, 1999). The structure of BAT is shown in figure 1.4. 
 
 
 
Figure 1.4. The structure of the brown adipose tissue.  
(http://www.pathologyoutlines.com/topic/softtissueadiposebrownfat.html) 
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1.6.2. White adipose tissue (WAT) 
  
The WAT is the primary site of energy storage in a lipid droplet of the adipocytes in 
the form of triglycerides (TGs). Its main role is to store TGs during energy 
consumption and to release fatty acid (FA) when energy expenditure exceeds energy 
intake (Dizdar and Alyamac, 2004).  It has recently been defined as an active 
endocrine organ that secretes a number of
 
signalling peptides or molecules, 
collectively known as adipokines (Galic et al., 2009). 
 
 Adipokines includes factors such as leptin, adiponectin, resistin, tumor
 
necrosis factor 
 (TNF ), interleukin-6 (IL-6), macrophage migration inhibitory factor and 
chemokine (Vazquez-Vela et al, 2008). Most of these factors have important roles in 
energy homeostasis, insulin sensitivity, immune function, inflammation, and even in 
tumor progression in the local oncogenic microenvironments.  Adipokines have 
important autocrine and paracrine roles
 
in regulating adipocyte differentiation and 
metabolism (Goralski et al., 2007; (Christiaens and Lijnen, 2010). A well-defined 
vascular system is present in adipose tissue, with every adipocyte surrounded by one 
or more capillaries as shown in Figure 1.5.  
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Figure 1.5. The structure of the white adipose tissue.  
The figure represents the structure of WAT with different cells type including adipocyte, indicated by 
the arrow and the vasculature which is the blood vessels supplying the cells with oxygen and nutrients  
(http://stevegallik.org/sites/histologyolm.stevegallik.org/htmlpages/HOLM_Chapter04_Page01.html.) 
 
 
 
 
Vasculature 
Adipocytes 
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1.6.3. The WAT as an endocrine organ 
Obesity is strongly associated with changes in the physiological function of adipose 
tissue, leading to insulin resistance, chronic inflammation, and altered secretion of 
adipokines (van Kruijsdijk et al., 2009).WAT is a complex and metabolically active 
organ, with a relevant important role in regulating whole-body metabolism. WAT is 
the largest energy storage organ, having an important lipid storing capacity in periods 
when energy input exceeds energy expenditure and with a lipolytic function (release 
of NEFA) during energy deprivation. In addition to its primary role as a fuel reservoir, 
white adipose tissue has been confirmed as a major endocrine organ, since the tissue 
synthesizes and secretes an array of sex steroids, and bioactive peptides termed 
“adipokines” (Scherer, 2006; Prieto-Hontoria et al., 2011).  
 
Adipokines participate in various metabolic processes including regulation of 
appetite, fat distribution, energy expenditure, inflammation, insulin sensitivity and 
insulin secretion. Via autocrine, paracrine and/or endocrine secretion, adipokines 
contribute to the modulation of adipogenesis, adipocyte metabolism and have 
systemic effects on appetite control, regulation of energy expenditure and activity, 
influence insulin sensitivity and energy metabolism in insulin sensitive tissues, such 
as liver, muscle and fat as well as insulin secretion in pancreatic beta cells (Trayhurm 
et al., 2006; Blüher, 2009; Blüher, 2013). The adipokine secretion pattern reflects 
adipose tissue function and seems to be important for determining the individual risk 
to develop metabolic and cardiovascular co-morbidities of obesity. With the 
development of adipose tissue inflammation and dysfunction, secretion of adipose 
tissue derived factors is significantly altered toward a diabetogenic, proinflammatory, 
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and atherogenic adipokine pattern (Blüher, 2013). Major adipokines secreted from 
WAT are shown in Figure 1.6.  
 
 
 
 
 
 
Figure 1.6. Major adipokines secreted from white adipose tissue and their roles.   
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1.6.4. Role of WAT in obesity 
 
The biological foundation of obesity is the overgrowth of WAT. Adipose tissue is a 
complex organ with major functions in metabolic and physiological processes 
(Daquinag et al., 2011). The main role of WAT is to store energy in form of lipids, 
while its other beneficial functions include thermal insulation aiding in the 
maintenance of body temperature, in addition to endocrine and immune system 
regulation. The main component of WAT is adipocytes; these are differentiated cells 
that accumulate lipid droplets. Weight gain occurs when the calorie expenditure is 
less than its intake, resulting in increased storage of lipids and an expansion of WAT 
by both hyperplasia (increase of cell number) and hypertrophy (enlargement of cells).  
 
Besides playing a major role in storage of energy, WAT is also an active endocrine 
organ secreting soluble molecules (adipokines) into the surrounding tissue and 
vasculature, which has systemic metabolic consequences. For this reason, any change 
in WAT has systemic effects and is often associated with serious health issues.  WAT 
is composed of stromal mesenchymal progenitors known as adipose stem cells (ASC), 
endothelial vascular cells and infiltrating leukocytes. This heterogeneous and dynamic 
pool of cells secretes a plethora of proinflammatory signals that contribute to a state 
of chronic inflammation in obesity. In fact, adipose tissue dysfunction plays a crucial 
role in the different obesity linked diseases including inflammation, insulin resistance 
and cancer (Prieto-Hontoria et al., 2011). Inflammation, being a strong platform for 
development of many diseases could be a major reason why obesity is accompanied 
by a range of disorders (Sirin and Kolonin, 2012).  
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1.7. The Adipose tissue and targeting molecules  
 
Protein targeting is the mechanism by which a cell transports proteins to the 
appropriate positions in the cell or outside the cell.  Targeting can be in the inner 
space of an organelle, any of several interior membranes, the cell's outer membrane, 
or its exterior via secretion, based on information contained in the protein itself 
(Wang et al, 2008). The peptides may be attached to various therapeutic agents for 
targeted delivery.  Attachment of therapeutic agents to targeting peptides results in 
selective delivery of the agent to a desired organ, tissue or cell type. Arap et al 
showed that, targeted delivery of chemotherapeutic agents and proapoptotic peptides 
to receptors located in tumor vasculature resulted in a marked increase in therapeutic 
efficacy and a decrease in systemic toxicity in tumor bearing animal models (Arap et 
al., 1998a, 1998b). 
 
Adipose-targeting peptides are peptide targeting the adipose tissue. These peptides 
may be used in methods for weight control, inducing weight loss and treating 
lipodystrophy syndrome. They can also be accomplished using other binding moieties 
selectively targeted to adipose receptors, such as a prohibitin receptor protein complex 
(Kolonin et al., 2004). These peptides could be used to control obesity and related 
conditions and would also be of potential use to treat HIV related adipose 
malformations such as lipodystrophia and/or hyperlipidemia (Zhang et al., 1999). 
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1.7.1. Prohibitin  
Prohibitin (PHB) is a human gene, which has been described in animals, fungi, plants 
and unicellular eukaryotes as growth-suppressive protein that has multiple
 
functions 
in the nucleus and the mitochondria. PHB is divided in two classes, termed Type-I 
(PHB1) and Type-II (PHB2) prohibitins, based on their similarity to yeast. Each 
organism has at least one copy of each type of PHB gene. PHB1 has a molecular mass 
of 30-32 kDa, whereas the closely related protein known as prohibitone or prohibitin 
2 (PHB2), has a mass of 37 kDa (Kasashima et al., 2006). The prohibitins (PHB1 and 
PHB2) together can form a high molecular weight complex. These complexes have 
been identified in both the mitochondria and the plasma membrane (Mishra et al., 
2005). 
 
Reports indicate that PHB is localized to the plasma membrane in certain cell types, 
and was suggested that it might function as a surface-binding site, (Sharma and Qadri, 
2004; Kolonin et al., 2004). Furthermore, these reports provide proof of principle that 
membrane-associated PHB can be targeted to modulate disease states (Sharma and 
Qadri, 2004; Kolonin et al., 2004). In summary, Sharma and Qadri, identified PHB as 
a component of the cell-surface-associated molecular complex in Caco-2 (human 
intestinal epithelium) cells, which binds to Vi (capsular polysaccharide of Salmonella 
typhi), the causative agent of typhoid fever in humans. The interaction of Vi with the 
PHB complex on Caco-2 cells resulted in the attenuation of IL-8 production by a 
process that appeared to involve the mitogen-activated protein (MAP) kinase 
pathway. These findings suggest that surface-bound PHB complexes might be 
important targets for modulation by small molecules of the inflammatory response 
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(Sharma and Qadri, 2004). PHB is also a highly conserved multi-functional protein, 
which is mainly
 
localized in the inner mitochondrial membrane (Mishra et al., 2005) 
and has been implicated
 
in regulating mitochondrial function in yeast (Kasashima et 
al., 2006). It has roles in transcription regulation, suppression of oncogenesis and 
metabolism. It has also been detected in serum from normal and cancer patients and 
known to be present on cell membranes and in lipid droplets released from adipocytes 
(Kolonin et al., 2004).  
 
PHB has potential roles as a tumour suppressor, an anti-proliferative protein, a 
regulator of cell-cycle progression, and it might also function as a cell-surface 
receptor (Mishra et al., 2005). Cell-associated PHB in the gastrointestinal tract has 
been implicated in protection against infection and inflammation and the induction of 
apoptosis in other tissues (Mishra et al., 2005). The diverse array of functions of PHB, 
together with the emerging evidence that its function can be modulated specifically in 
certain tissues, suggest that targeting PHB would be a useful therapeutic approach for 
the treatment of variety of diseases  including inflammation, obesity and cancer 
(Kolonin et al, 2004; Schleicher et al., 2008). 
 
1.8. Adipogenesis 
Adipogenesis is the process by which undifferentiated precursor cells differentiate 
into fat cells. It involves production and formation of fat. Its main role is to store 
energy in the form of fat. The nuclear hormone receptor PPARg is the central 
regulator of adipogenesis and plays a dominant role in fat tissue development 
(Vazquez-Vela et al., 2008). 
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1.9. Lipogenesis  
 
Lipogenesis is the synthesis of esterified fatty acids (FAs), which form triglycerides 
(TGs) from carbohydrates or other energy sources acquired in the diet. In rats, 
lipogenesis occurs in liver and WAT, whereas in humans lipogenesis contributes 
mildly to the fat balance (Vazquez-Vela et al., 2008). It occurs predominantly in liver 
and to a lesser extent in adipose tissue, even with high-carbohydrate diets. In rodents, 
nutritional status and small changes in insulin levels are factors that influence 
lipogenesis rate (Vazquez-Vela et al., 2008). Lipid synthesis is augmented during 
postprandial state and after carbohydrate consumption and is inhibited under fasting 
conditions. Lipid accumulation in adipose tissue depends on circulating FA uptake 
(Vazquez-Vela et al., 2008).  
 
FAs are provided by the enzymatic hydrolysis of TG contained in the chylomicrons 
by the lipoprotein lipase. After FAs enter the adipocyte, reesterification is necessary 
for lipid storage in TG form. Several enzymes involved in adipose tissue lipogenesis 
are induced by insulin. These are fatty acid synthase (FAS), acetyl CoA carboxylase 
(ACC) and malic enzyme (ME). Newly synthesized FAs are used as substrates in TG 
synthesis (Sul and Wang, 1998). Insulin-mediated stimulation of lipogenesis in 
response to nutritional status is the result of an increase in the enzyme activities 
involved in FA biosynthesis, as well as an increase in the gene expression of these 
enzymes (Vazquez-Vela et al., 2008). 
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1.10. Non-esterified fatty acids (NEFA)  
 
The NEFA are the fraction of plasma fatty acids. The NEFA impairs insulin-
stimulated glucose uptake and glycogen synthase activity in skeletal muscle. 
Circulating NEFA stimulate β-cell insulin secretion which eventually contribute in the 
development of insulin resistance in both skeletal muscle and liver, prominent 
abnormalities in obese individuals (Mohamed-Ali et al., 1998).There is a widespread 
acceptance in the literature that plasma NEFA also called free fatty acids (FFA), can 
mediate many adverse metabolic effects, mostly insulin resistance. Elevated NEFA 
concentrations in obesity are thought to arise from an increased adipose tissue mass. It 
is also argued that the process of fatty acid mobilization from adipose tissue, normally 
suppressed by insulin, itself becomes insulin resistant, thus lipolysis is further 
increased, potentially leading to a vicious cycle (Karpe et al., 2011).  
 
1.11. Angiogenesis 
 
Angiogenesis also known as neovascularization is a multistep process of new blood 
vessel formation from pre-existing vasculature. It is crucial for all tissue growth, 
expansion and repair (Cao, 2010). Angiogenesis usually takes 2 forms: sprouting and 
unsprouting. Sprouting angiogenesis is the development of new blood vessels through 
proteolytic degradation of the extracellular matrix, migration/proliferation of 
endothelial cells (ECs), new organization of the luminal membrane, and maturation of 
endothelial cells to functional capillaries (Pandya et al., 2006). New vessels can arise 
from postcapillary venules (angiogenesis) or from precapillary arterioles 
(arteriogenesis). Nonsprouting angiogenesis occurs by intussuception, which means 
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the splitting of primary vessels by transcapillary pillars. Most normal angiogenesis 
occurs in the embryo. In adults, occurs during the ovarian cycle, pregnancy, and 
during physiologic repair processes such as wound healing or endometrial regrowth. 
In normal circumstances, angiogenesis is a highly ordered process that is under tight 
regulation by both angiogenesis-inducing factors and angiogenesis-inhibiting factors. 
These factors include soluble growth factors secreted from cells, such as vascular 
endothelial growth factor (VEGF), angiopoietins, fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF), transforming growth factor (TGF), and 
membrane- bound molecules, such as integrins, cadherins, and ephrins (Liu and 
Deisseroth, 2006; Pandya et al., 2006). 
 
1.11.1. Process of angiogenesis  
 
During angiogenesis, the diseased or tumor cells produce and release angiogenic 
growth factors (proteins) that diffuse into the nearby tissues. The angiogenic growth 
factors bind to specific receptors located on the endothelial cells (EC) of nearby 
preexisting blood vessels. Once growth factors bind to their receptors, the endothelial 
cells become activated. Signals are sent from the cell's surface to the nucleus. The 
endothelial cell's machinery begins to produce new molecules including enzymes. 
Enzymes will then dissolve tiny holes in the sheath-like covering (basement 
membrane) surrounding all existing blood vessels. The endothelial cells will begins to 
divide or proliferate, and migrate out through the dissolved holes of the existing 
vessel towards the diseased tissue (tumor). Specialized molecules called adhesion 
molecules, or integrins serve as grappling hooks to help pull the sprouting new blood 
vessel sprout forward. Additional enzymes (matrix metalloproteinases, or MMP) are 
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produced to dissolve the tissue in front of the sprouting vessel tip in order to 
accommodate it. As the vessel extends, the tissue is remolded around the vessel. 
Sprouting endothelial cells roll up to form a blood vessel tube. Individual blood vessel 
tubes connect to form blood vessel loops that can circulate blood. Finally, newly 
formed blood vessel tubes are stabilized by specialized muscle cells (smooth muscle 
cells, pericytes) that provide structural support. Blood flow then begins (Pandya et al., 
2006). 
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Table1.4. Selected stimulatory and inhibitory regulators of angiogenesis. 
  (Pandya et al., 2006). 
 
Stimulators Inhibitors 
 
VEGF Angiostatin 
Angiopoietin-1      Anti-angiogenic anti-
thrombin 
β-Estradiol             Canstatin 
IL-8                        Fibronectin fragment 
Leptin   Heparinases 
MCP-1                   IFN-α,β,χ 
TNF-α                  Prolactin 16 kDa fragment 
Angiogenin TSP-1 
MMPs IL4, IL12, IL18 
FGF    Endostatin (collagen XIII 
fragment) 
 
 
Abbreviations: VEGF-vascular endothelial growth factor; IL8-interleukin 8; MCP-1-macrophage 
chemoattractant protein; MMPs-matrix metalloproteases, TSP- Thrombospondin and TNF-
tumor necrosis factor 
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Table 1.5. Selected anti-angiogenic agents and their mechanism of action. 
  (Brakenhielm et al., 2004; Clarke and Sharma, 2006). 
 
Inhibitors Mechanism of action 
 
Angiostatin Inhibit cell proliferation 
Induce apoptosis of endothelial cells 
Inhibit binding activity of VEGF and bFGF 
αVβ3 Induce apoptosis of endothelial cells 
Vasostatin Inhibit cell proliferation of endothelial cells 
Interferon –alfa Inhibit endothelial cells migration 
Bevacizumab Monoclonal antibody against or which bind to VEGF 
Delay tumor  growth 
Prevent VEGF from binding to its receptoe 
Prolactin 16 kDa fragment Inhibit VEGF and Bfgf 
Thalidomine Reduction of TNF alpha, bFGF and VEGF 
TNP 470 Reduce neovasculation in the adipose tissue 
Inhibit endothelial cells growth 
Endostatin (collagen XIII 
fragment) 
Inhibit cell migration, cell proliferation and survival of 
endothelial cells 
Platelet factor 4 Inhibit binding of VEGF and bFGF 
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1.11.2. Regulation of adipose tissue-related angiogenesis 
 
Both WAT and BAT produce and secrete many different types of proangiogenic 
factors such as vascular endothelial growth factor (VEGF)-A and hepatocyte growth 
factor (HGF), which are two key angiogenic factors specifically produced by 
adipocytes. Other adipose tissue-derived factors with proangiogenic effects include 
VEGF-B, VEGF-C, placental growth factor (PlGF), fibroblast growth factor (FGF)-2, 
leptin, platelet-derived growth factor (PDGF), tumor necrosis factor (TNF), tissue 
factor (TF), plasminogen activators and cathepsins. Adipose tissue also produces 
endogenous antiangiogenic factors, such as adiponectin, thrombospondin (TSP)-1, 
TSP-2, ADAM and ADAMTS family members. Thus, the regulation of angiogenesis 
in adipose tissue may depend on the local balance between proangiogenic and 
antiangiogenic factors (Christaens and Lijnen, 2010). 
1.11.3. Angiogenesis and obesity  
Emerging evidence shows that adipose depot development and tissue growth is 
coupled to angiogenesis. In preclinical models, delivery of antiangiogenic agents 
effectively prevents development of obesity in genetic and high fat-diet-fed obese 
mice. These angiogenesis inhibitors do not cause obvious adverse effects in animals 
and anti-obesity effect is reversible (Pandya et al., 2006). Adipose tissue and blood 
vessels intimately interact with each other throughout the life hood. In addition to 
supplying nutrients and oxygen to the adipocyte, blood vessels also provide growth 
and survival factors to co-opt the growth and regression of adipose depots throughout 
the adulthood. It has recently been reported that a fraction of adipocyte stem cells 
reside within the vascular cell population, suggesting that angiogenic vessels may 
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provide precursors for adipose tissue expansion. Angiogenic vessels are not only 
required for adipose tissue growth but may also actively participate in regulation of 
adipose metabolism and energy expenditure. For example, in the metabolically active 
brown adipose tissue the vascular density is considerably higher than those in white 
adipose tissues (Pandya et al., 2006). 
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1.12. Nanotechnology 
 
The term nanotechnology is derived from the Greek word nano, meaning dwarf, 
which applies the principles of engineering, electronics, physical and material science, 
and manufacturing at a molecular or submicron level (Sahoo et al., 2007). 
Nanotechnology can be described as a branch of engineering that involves research 
and technology development. It involves working with small particles at atomic, 
molecular and macromolecular scale. It generally deals with structures of the size 100 
nanometers or smaller, and involves developing materials or devices within that size 
(Paull, 2008).  
 
Recently, nanotechnology-based drug delivery systems have shown considerable 
potential for treatment of disease. The technological advantages of NPs used as drug 
delivery systems are high stability, high carrier capacity, feasibility of incorporation 
of both hydrophilic and hydrophobic agents, ease of chemical synthesis, less toxicity, 
and the feasibility of variable routes of administration (Park, 2007). Various NPs 
functionalized with different biomolecules have been successfully used in many 
therapeutic and research applications due to their versatility, ease of chemical 
synthesis, less toxicity and unique properties (McNeil, 2005). Figure 1.7 shows 
medical application of nanotechnology.  
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Figure 1.7. Medical application of nanotechnology. 
 The figure represent application of nanotechnology in both research and clinical (Reprinted with 
permission from Journal of Leucocyte in Biology, Copyright, 2005 (McNeil, 2005)  
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1.12.1. The use of nanoparticles in nanotechnology 
 
NPs are submicron-sized colloidal particles with a therapeutic agent of interest that 
are encapsulated within the polymeric matrix or conjugated onto the surface (Misra et 
al., 2010). The sizes range from 10-1000 nm in diameter. NPs offer a great possibility 
for biomedical application, not only to deliver pharmaceutics, but also to be used as 
novel diagnostic and therapeutic approaches (Jain, 2005; Abdelhalim and Moussa, 
2013). Many types of NPs can be used as imaging and drug-delivery systems and 
these can be formulated from diverse materials with unique architectures to serve as a 
possible drug-delivery vehicle to treat a particular disease (Parveen et al., 2012). 
These includes: carbon nanotubes, dendrimers, nanoshells, nanorods, liposomes, 
magnetic NPs, quantum dots (QDs) and gold NPs (GNPs) (Kim, 2007; Hossen et al., 
2010; Qiu et al., 2010); Papasani et al., 2012; Parveen et al., 2012).  
 
Concern has been expressed about the introduction of metallic NPs into the human 
body for therapeutic purposes and possible toxic effects. The small size of particles, 
particularly those below 20 nm, makes them versatile therapeutic tools for drug 
delivery. Their biological effects may vary according to size, chemical composition, 
surface structure, solubility, shape, and aggregation (Goodman et al., 2004; Connor et 
al., 2005). QDs may release potentially toxic cadmium and zinc ions into cells. 
However, because of their protective coating made of zinc-selenide (ZnS), the QDs 
have minimal toxicity on cells (Cai and Chen, 2008). Studies using 2-nm core GNPs 
have shown that cationic particles are moderately toxic, whereas anionic particles are 
quite nontoxic (Goodman et al., 2004; Connor et al., 2005). So therefore, this study 
will focus on the use of GNPs and QDs as drug delivery and imaging agents. 
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1.13. Gold nanoparticless (GNPs)  
 
The gold nanoparticless (GNPs) also known as nanogold or colloidal gold are 
colloidal suspension of sub-micrometre-sized particles of gold in a fluid (Ghosh et al., 
2008). The GNPs have been synthesized by an array of methods which mainly are 
based on the reduction of chloroauric acid in the presence of a stabilizing agent 
(Tiwari et al. 2011). The most commonly used method, the citrate synthesis method, 
involves reduction of chloroauric acid using trisodium citrate resulting in the 
formation of GNPs (Liang et al., 2007; Turkevich et al., 1951; Tiwari et al., 2011). 
The liquid is usually either an intense red colour (for particles less than 100 nm), or a 
dirty yellowish colour (for larger particles). The size of GNPs is determined mainly 
by the salt concentration, temperature and rate of addition of reactants resulting in size 
range of 10–25 nm (Ghosh et al., 2008). However, the size range from 1–100 nm or 
more can also be achieved by varying the salt concentration and temperature (Tiwari 
et al., 2011). 
 
The GNPs are non-toxic, inert, stable, sub-micrometer sized particles (mostly used as 
gene and drug delivery agent), (Ghosh et al., and 2008). Among other nanocarriers, 
GNPs are emerging as a lead candidate in the field of nanotechnology because they 
can be easily tailored to a desired size from 0.8 to 200 nm, their ease of preparation, 
they can be easily modified to impart various functionalities and good 
biocompatibility and can be readily conjugated to proteins and other molecular 
species without altering the biological activity of the conjugated species (Abdelhalim 
and Mady, 2011; Wang et al., 2008).  
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Additionally, GNPs have unique optical properties such as distinctive bands in the 
visible region, due to surface plasmon oscillation of free electrons (Wang et al., 
2008). They can be used as targeted molecules, drug carriers and as an image contrast 
agent (McNeil, 2005 and Ghosh et al., 2008). GNPs are capable of delivering large 
biomolecules. Tunable size and functionality make them a useful scaffold for efficient 
recognition and delivery of biomolecules (Ghosh, 2008; Abdelhalim and Moussa, 
2013). 
 
1.13.1. Application of GNPs 
 
GNPs show unique optical properties as indicated in section 1.9.1.1; this property 
allows the use of NPs for many applications, Figure 1.8 (Niidome et al., 2006; 
Chanda et al., 2008; Jiao et al., 2011). GNPs have the potential application in field 
such as electronics, optoelectronics and biosensors. Most application of GNPs as 
sensors are based on detecting the shift in surface plasmon resonance (SPR) peaks due 
to either change in the local dielectric constant of the NPs to adsorbed bio-molecules 
or due to biomolecules induced agglomeration of NPs (Ghosh et al., 2008). They have 
a wide range of applications in areas such as catalysis, medical diagnostics and 
biological imaging, Figure 1.8, (Ghosh et al., 2008; Parimal et al., 2010)). 
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Figure 1.8. Schematic representation for the applications of GNPs 
 
 
 
GNPs have a high surface reactivity and biocompatible properties and have gained 
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due to their interesting size dependent chemical, electronic and optical properties 
(Poportzer et al., 2008). They are also used for in vivo molecular imaging and 
therapeutic applications, including cancer detection and therapy (Poportzer et al., 
2008). Studies have been conducted on NPs functionalized with fluorophores, 
peptides, cell adhesion molecules, aptamers or other biomolecules to target specific 
tissues and thereby holding promise to be used for imaging of tumors, drug delivery 
and detection of apoptosis (Sun et al., 2008; Chanda et al., 2010). For GNPs to be 
effective as a pharmaceutical, it is essential to have a firm understanding of their 
biodistribution/accumulation in living systems (Chanda et al., 2010). The 
biodistribution of drug carriers is often affected by the route of administration (Arvizo 
et al., 2010). NPs used as drug carriers tend to have a longer retention time, generally 
in the local lymph node, compared to the free drug when administered 
subcutaneously, intramuscularly, or topically. However, the biodistribution of the NPs 
largely depends on its surface charge and hydrodynamic radius (Arvizo et al., 2010). 
1.13.2. Biodistribution of GNPs  
It was shown in the literature that the size and surface-capping of GNPs play an 
important role in the biodistribution of GNPs in mice (Cho et al., 2009; Morais, 
2011).  Studies done by Sonavane et al., (2008) also showed that naked gold can 
accumulate in the liver and spleen. The size-dependent organ distributions of GNPs 
have been investigated, and the results showed that small GNPs of 5–15 nm had wider 
organ distribution than that of large GNPs of 50–100 nm, and liver and spleen were 
the dominant targeted organs (De jong et al., 2008 and Cho et al., 2009; Papasani et 
al., 2012). Meanwhile, it has been found that GNPs with a long blood circulation time 
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can accumulate in the liver and spleen, and have obvious effects on gene expression 
(Balogh et al., 2007; Kim et al., 2009)         
   
Efficient delivery of GNPs into a living system requires overcoming natural 
biological barriers such as the cell membrane and the reticuloendothelial system 
(RES) (Niidome et al., 2006). For specific tumor targeting, GNPs face additional 
challenges from receptor specificity and intratumor barriers. Potential approach for 
optimizing GNPs delivery is particle size or acquisition of surface modification. For 
example, large GNPs are quickly opsonized by blood and eliminated by the RES in 
mammalian cells (Woodle et al., 1994; Raynal et al., 2004; Roger and Basu 2005; 
Paciotti et al., 2006).  
 
To bypass RES, antibiofouling agents such as thiol-derivatized poly-ethylene glycol 
(PEG-SH) have been grafted onto GNPs surface as secondary coating. It has been 
observed that this secondary coating could delay RES clearance to liver from 0.5 
hours to 72 hours in a mice model, an approximately 150-fold improvement compared 
with the unmodified CTAB-capped GNPs (Niidome et al., 2006). Several 
investigators have grafted different delivery platforms onto GNPs surface to attempt 
cellular selectivity, internalization, and localization within heterogeneous population 
of cancer cells in solid tumors (Chen et al., 2008). Organs of the RES can efficiently 
accumulate nanoparicles via opsonization, that is, NPs could bind to antibody in the 
plasma and are subsequently recognized by the phagocyte-rich RES 
(Balasubramanian et al., 2010; Zhang et al., 2012) 
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Opsonization is the process by which a foreign organism or particle becomes covered 
with opsonin proteins, thereby making it more visible to phagocytic cells. 
Phagocytosis is a cellular process involving the engulfing or removal of foreign 
materials from the bloodstream (OwensIII and Peppas, 2006). Together, these two 
processes form the main clearance mechanism for the removal of undesirable 
components larger than the renal threshold limit from the blood. In the case of 
polymeric NPs, which cannot normally be destroyed by the phagocytes, sequestration 
in the mononuclear phagocytic system (MPS) organs typically occurs. If the 
polymeric NPs is non-biodegradable, then accumulation of particles in these organs, 
most commonly the liver and spleen, occur leading to toxicity and other negative side 
effects (OwensIII and Peppas, 2006; Gaumet et al., 2008). 
 
1.13.3. Surface coating of GNPs 
 
Studies have shown that factors such as size, shape, surface coating and charge, 
affects physicochemical properties of GNPs, with the size being a major determinants 
for biodistribution (De Jong et al., 2008; Ghosh et al., 2008). Functionalization 
through the addition of ligands on the surface of the GNPs is of great interest, as 
capping can grant some slyness capacity to remain undetected by the RES, thus 
prolonging their half-life in the bloodstream. In addition, coating can also be 
employed as a targeting strategy to guide the nanoparticle to a desired organ. These 
capping agents can be varied in nature including polymers like polyethylene glycol 
(PEG) and peptides. Peptides as surface capping agents of GNPs are advantageous as 
they can increase stability, biocompatibility and solubility in aqueous solution. 
Studies on PEG-coated GNPs biodistribution have shown that NPs exhibit longer 
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blood circulation times both in mice and in rat. Nevertheless, liver and spleen 
remained the preferential sites of the accumulation of the PEG-GNPs (Morais et al., 
2011). 
 
Longer circulation of NPs, with minimum uptake by the cells of RES is desirable in 
terms of better targetability of the NPs. The major obstacle to active targeting of 
colloidal particles in the body system has been the ability of the cells of the RES to 
rapidly remove intravenously applied particulates from the systemic circulation. The 
usual strategy taken to avoid the uptake of NPs is by coating the particle surface with 
hydrophilic polymers, like PEG derivatives such as poloxamers and poloxamines. It 
has been demonstrated that the RES evasion and long circulation by the particles are 
possible if the NPs are of ultra-low size (usually <100 nm diameter) and have surface 
hydrophilicity (Lasagna-Reeves et al., 2010, Zhang et al., 2012.  According to 
Sonavane et al., 2008, smaller GNPs sizes, such as 15 and 50 nm revealed higher 
amount of gold in the blood after 24 h of intravenous administration while GNPs of 
higher particle sizes including 100 and 200 nm showed problem of settling in distilled 
water. Hence, it is necessary to stabilize the GNPs with biodegradable or 
biocompatible stabilizer.  
1.13.4. Cytotoxicity of GNPs 
The toxicity of NPs is thought to depend on the size, surface area, composition, and 
shape of the nanomaterial (Abdelhalim and Mady, 2011). The NPs size also plays a 
role in how the body responds, distributes, and eliminates materials.  Therefore, for 
applications of GNPs in therapy and drug delivery, it is necessary to know 
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bioaccumulation and systemic toxicity associated with the NPs (Kamat, 2002; 
Abdelhalim and Mady, 2011). 
 
The cytotoxicity of GNPs in human cells has been studied (Lu et al., 2012). Results 
have shown that GNPs are nontoxic up to 250 mM, while ionic gold shows obvious 
cytotoxicity at 25 mM (Connor et al., 2005). The toxicity of GNPs in vivo is 
determined by many parameters including dose, route of exposure or administration, 
metabolism, excretion, and immune response. The toxicologic profiles of 
nanomaterials might also be determined by nanomaterial chemical composition, size, 
shape, aggregation, and surface coating (Connor et al., 2005).  GNPs are stable and 
non-toxic, so they do not degrade during the transport and are safe to normal tissue 
(Lu et al., 2012). 
 
1.14. Targeted drug delivery 
 
Drug delivery is the method of administering a pharmaceutical compound to achieve a 
therapeutic effect in humans or animals. Drug delivery technologies can either modify 
drug release profile, absorption, distribution and/or elimination for the benefit of 
improving drug efficacy and safety. Current efforts in the area of drug delivery 
include the development of targeted delivery in which the drug is only active in the 
target area of the body (e.g., cancer), and sustained release formulations in which the 
drug is released over a period of time in a controlled manner (Ravi Kumar, 2008; 
Farokhzad and langer, 2009). 
Targeted drug delivery can be defined as the process of releasing or delivering a 
bioactive agent at a specific rate and at a specific site (Papasani et al., 2012). The goal 
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of a targeted drug delivery system is to prolong, localize, target and have a protected 
drug interaction with the diseased tissue. This improves efficacy, while reducing side 
effects (Manish and Vimukta, 2011; Papasani et al., 2012). Most conventional 
anticancer agents do not differentiate between cancerous and normal cells, leading to 
systemic toxicity and adverse effects (Parveen and Sahoo, 2008).  
 
One of the better strategies is to engineer NPs that are able to target to tumor cells or 
tumor environment after systemic delivery. This is achieved by conjugating NPs with 
a molecule or biomarker that binds to receptors found on tumor cells (Brannon-
Peppas, 2004). Functional NPs are prepared by covalently linking them to biological 
molecules such as peptides, proteins, nucleic acids, or small-molecule ligands (Calle 
et al., 2003; Flegal et al., 2007).  The NPs technology holds great promise in 
simultaneously diagnosing disease, providing targeted drug delivery with minimal 
toxicity, and monitoring treatment (Parveen and Sahoo, 2008). The NPs-based drug-
delivery systems provide an advantage over free drugs, improving delivery efficiency, 
solubility, in vivo stability and biodistribution. Figure 1.9 shows drug targeted NPs to 
disease cell. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1                                                                                                                           Literature review 
49 
 
 
 
 
 
 
Figure 1.9. Mechanism on peptide targeted NPs, showing targeted delivery to disease cells. 
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1.14.1. GNPs as targeted drug delivery agent 
 
The GNPs are currently being investigated for their potential uses in targeted cancer 
detection and treatment. They can be engineered to target specific tissues or cancer 
cells for use in molecular imaging, making it possible to see diseased cells that are 
undetectable by conventional imaging methods (Akerman et al., 2002; Koo et al., 
2005; Jiao et al.,2011) The small size and configuration of NPs also allow them to 
pass through biological membranes into cells, where they can act as targeted drug 
delivery systems for malignant cells while sparing healthy neighboring cells, (Kamat, 
2002, Fent et al., 2009). Nanoparticle-based drug delivery systems have shown 
considerable potential for treatment of disease (Park, 2007).  
 
Over the past few decades, GNPs have received a lot of attention in a broad range of 
biomedical fields, including biomolecular sensing, drug delivery, photothermal cancer 
therapy, and X-ray computed tomography (CT) imaging. Particularly in drug delivery, 
GNPs have emerged as an attractive candidate for the creation of efficient nucleic 
acid delivery systems, mostly due to their excellent biocompatibility, versatility in 
synthesis, high surface-area-to-volume ratio, and facile surface functionalization 
through intracellularly displaceable gold-thiol linkages (Manish and Vimukta, 2011; 
Papasani et al., 2012).  Furthermore, GNPs functionalized with bio-recognizable 
ligands have been developed for specific cell-targeting and delivery applications 
(Kong et al, 2011). GNPs have been proposed for diverse biomedical applications due 
to their unique surface, electronic, and optical properties. Because of the strong and 
size-tunable surface plasmon resonance, fluorescence, and easy-surface 
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functionalization, GNPs have been widely used in biosensors, cancer cell imaging, 
photothermal therapy, and drug delivery (Ghosh et al., 2008). 
 
1.15. Quantum dots (QDs) 
 
QDs are nanometer sized fluorescent semiconductors that are increasingly used as 
labeling and imaging tools in medical research (Xiao and Barker, 2004; Garon et al., 
2007; Savla et al., 2011). They range from 2-10 nanometers in diameter and can glow 
or fluoresce when stimulated by a light source such as laser (Garon et al., 2007).  
They are near-spherical semiconductor nanocrystals composed of a Cadmium 
selenide (CdSe), Cadmium sulphide (CdS) or Cadmium Telluride (CdTe) core 
together with a Zinc sulphide (ZnS) shell and have recently attracted major interest as 
novel fluorophores (Byers and Hitchman, 2011).  
 
They can be specifically attached to biological materials such as cells, proteins and 
nucleic acids making them powerful agents (Byers and Hitchman, 2011). QDs can be 
designed to emit light at any wavelength from the infrared to visible to ultraviolet. 
Larger QDs emit red light, whereas smaller crystals emit light at the blue end of the 
spectrum. These nanometer-sized particles are able to display any chosen colour in 
the entire ultraviolet-visible spectrum through a simple change in their size or 
composition as indicated in Figure 1.10 (Zrazhevskiy and Gao, 2009).  
 
QDs have physical properties, such as high quantum yield and resistance to photo 
bleaching, that make them attractive molecular probes for tracking hematologic cells 
(Garon et al., 2007). They are photostable and size tunable, with narrow, symmetric 
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emission spectra and broad continuous excitation. They allow excitation of multiple 
QDs with a single wavelength. In addition, QDs are inorganic and so these are very 
stable, and their inert surface coating makes them less toxic than organic dyes 
(Jamieson et al., 2007). QDs fluorescence is so bright that it is possible to detect a cell 
carrying a single crystal. These properties make QDs very attractive luminescent 
labels for biological applications (Chalmers et al., 2007).  
 
More importantly, their strong and stable photo luminescent properties make them 
promising candidates for use in bio-imaging applications, they can emit different 
colors, based on pre-determined biological tags/signals. This means that scientists can 
attach quantum dots to a given protein or receptor to observe normal or abnormal cell 
functions (Pathak et al., 2007). Unlike conventional organic dyes, QDs are highly 
photostable (Wickline et al., 2003; Jamieson et al., 2007). This allows them to track 
cell processes for longer periods of time and to shed more light on molecular 
interactions. 
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Figure 1.10. Different sizes, colour and emission spectra of QDs 
 (Reprinted with permission from Nano today, Copyright, 2009,Zrazhevskiy and Gao, 2009) 
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1.15.1. Optical properties of QDs 
The QDs are inorganic fluorescent semiconductor NPs. The quantum confinement 
effects give rise to unique optical and electronic properties in QDs, giving them 
numerous advantages over current fluorophores, such as organic dyes, fluorescent 
proteins and lanthanide chelates. The classic and most commonly used QDs consist of 
CdSe core and a shell layer made of ZnS or CdS (Zrazhevskiy and Gao, 2009).  
Fluorescence properties of QDs are determined by the core materials and the shell 
layer (Yezhelyer et al., 2001). For biological imaging applications, QDs can be made 
water soluble by exchanging with bifunctional ligands or coating with amphiphilic 
polymers that contain both a hydrophobic segment or side chain (mostly 
hydrocarbons) and a hydrophilic group (Yezhelyer et al., 2001; Rosenthal et al., 
2011).  
 
The novel optical property of QDs arises from quantum confinement effect of the 
semiconductor materials. This refers to the size and composition dependence of the 
semiconductor band gap energy (Garon et al., 2007). Photostability of QDs is a 
critical feature in most fluorescence applications, and is an area in which QDs have 
singular advantage. Unlike organic fluorophores which bleach after only a few 
minutes on exposure to light, QDs are extremely stable and can undergo repeated 
cycles of excitation and fluorescence for hours with a high level of brightness and 
photobleaching threshold (Jamieson et al., 2007). QDs have been shown to be more 
photostable than a number of organic dyes. QDs also have a long fluorescent lifetime 
after excitation, which may be taken advantage of in time-gated imaging. The fast 
fluorescence emission of organic dyes upon excitation coincides closely with short-
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lived autofluorescence background from many naturally occurring species, reducing 
the signal-to-noise ratio. Conversely, QDs emit light with a decay time in the order of 
a few tens of nanoseconds (30–100 ns) at room temperature, which is slower than the 
autofluorescence background decay, but fast enough to maintain a high photon 
turnover rate (Walling et al., 2009). 
 
1.15.2. Toxicity of QDs 
 
One of the major issues that hinder the application of QDs to human subjects is the 
concern about their safety. Cadmium and selenium are potential hazard for 
neurological and genitourinary toxicity (Jamieson et al., 2007). Cytotoxicity of QDs 
has been observed in a large number of in vitro studies affecting cell growth and 
viability (Wickline et al., 2003). The extent of cytotoxicity has been found to be 
dependent upon a number of factors including size, dose, and surface chemistry of 
QDs. A number of mechanisms have been proposed to be responsible for QDs 
cytotoxicity. These include desorption of free Cd (QDs core degradation) free radical 
formation, and interaction of QDs with intracellular components (Wickline et al., 
2003; Jamieson et al., 2007). 
 
 
 
 
 
 
 
 
 
 
Chapter 1                                                                                                                           Literature review 
56 
 
1.15.3. Application of QDs 
The QDs have been used for labelling, imaging, detection, and quantification of 
bacteria (Savla et al, 2011). Beside in vivo and cellular imaging, QDs can be used for 
a wide range of other applications (Rosenthal et al., 2011), relevant to the life 
sciences, such as fixed tissue analysis, spectral encoding of microparticles, and as 
quantitative analysis of ions (Larson et al., 2003; Yezhelyev et al., 2007). Figure 1.11 
shows multifunctionality of QDs. 
 
Multi-QD labeling of the diseased site (by coating QDs with targeting molecules of 
different emission wavelengths) can provide more information on the state and 
evolution of the disease (Jiang et al., 2004). Several groups report homing of QDs to 
biological targets in vivo. Targets have included tumours, vasculature in several 
different tissue targets (Lim et al., 2003) and also a number of targets in necropsy and 
tissue sections after in vivo injection of QDs. One group used antibody-conjugated, 
PEG-encapsulated QDs to target a prostate-specific membrane antigen, a cell surface 
marker for prostate epithelium, which is also expressed in the neovasculature of a 
large number of nonprostatic primary carcinomas (Weissleder, 2001; Pathak et al., 
2007)  Another group report the synthesis of a tumour-specific chimera phage 
incorporating a streptavidin- binding site to which QDs may be attached, which is 
able to specifically target and fluorescence tumour (Chen et al., 2004).  
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Figure 1.11.  Schematic representation for the application of QDs 
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1.15.4. Biofunctionalization of QDs 
 
To make QDs more useful for molecular imaging and other biological applications, 
QDs need to be conjugated to biological molecules without disturbing the biological 
function of these molecules. Biomolecules including peptides, proteins and 
oligonucleotides have been successfully linked to QDs. Several successful approaches 
have been used to link biological molecules to QDs (Alivisatos et al., 2005). These 
includes non-specific adsorption, electrostatic interaction, mercapto (-SH) exchange, 
and covalent linkage (Xing and Rao, 2008). The biological molecules containing thiol 
groups can be conjugated to the QDs surface through mercapto exchange process. 
Unfortunately, since the bond between Zn and thiol is not very strong and is dynamic. 
Biomolecules attached to QDs in this way can readily dissociate from the nanoparticle 
surface, causing QDs to precipitate from the solution. It has also been reported that 
simple small molecules, such as oligonucleotides and various serum albumins are 
readily adsorbed to the surface of water soluble QDs. This adsorption is nonspecific 
and depends on ionic strength, pH, temperature, and the surface charge of the 
molecule (Hanaki et al., 2003; Mahtab et al., 2000).  
 
Mattoussi and coworkers presented a method of conjugating proteins to QDs surfaces, 
using electrostatic interactions. The protein of interest was engineered with a 
positively charged domain (poly histidine), which in turn interacted electrostatically 
with the negatively charged surface of dihydrolipoic acid (DHLA)-capped QDs. The 
protein-QDs conjugates prepared in this way were stable and the fluorescence 
quantum yield was even higher than that from the non-conjugated QDs (Mattousi et 
al., 2000 and Xing et al., 2008). A more stable linkage is obtained by covalently 
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linking biomolecules to the functional groups on the QD surfaces using cross-linker 
molecules (Xing et al., 2007). This method is the most commonly used approach for 
making biofunctionized QDs for in vitro cell labelling and in vivo imaging purposes.  
 
Most water solubilization methods result in QDs covered with carboxylic acid, amino 
or thiol groups. Under these situations, it is easy to link QDs to biological molecules 
which also have these functional groups. For example, the cross-linker 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) is commonly used to link NH2 and COOH 
groups, whereas 4-(N-maleimidomethyl)- cyclohexanecarboxylic acid N-
hydroxysuccinimideester (SMCC) can be used to cross-link -SH and -NH2 groups. 
Using these methods, there have been numerous reports of conjugating QDs with 
various biological molecules, including biotin oligonucleotides peptides and proteins 
including avidin/streptavidin albumin adaptor proteins (e.g. protein A, protein G) and 
antibodies (Pinaud et al., 2004; Xing et al., 2007; Yang et al., 2010; Chirra et al., 
2011).  
 
 For biological applications, QDs must be linked to biomolecules without altering the 
biological activity of the conjugated form. A number of successful conjugation 
methods have been developed, including covalent and non-covalent attachment 
methodologies. Specific conjugation methodologies include direct adsorption on the 
quantum dot surface, the use of inert polymer coatings, or biotin-streptavidin linkages 
(Bruchez et al., 1998; Walling et al., 2009; Chirra et al., 2011). Another common 
conjugation scheme employs the biotin-streptavidin linkage, which requires coupling 
of the quantum dot to streptavidin. Quantum dot-streptavidin conjugates are useful 
because a wide range of proteins and other biomolecules can be biotinylated. These 
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conjugates have applications in staining and labelling, live tracking and drug 
screening (Bruchez et al., 1998; Jaiswal et al., 2003; Walling et al., 2009; Chirra et 
al., 2011). 
 
1.16. Molecular imaging 
 
Molecular imaging is an emerging field that integrates molecular biology with in vivo 
imaging in order to gain information regarding biological processes and to identify 
diseases based on molecular markers. It is a new approach for detecting diseases 
much earlier, visualizing biological processes at the cellular and molecular level in 
living organisms, and detecting changes in biochemistry. Currently, positron emission 
tomography and single photon emission tomography are the main molecular imaging 
modalities in clinical use (Ghosh et al., 2008).  
 
However, they provide only functional information regarding molecular processes and 
metabolites, which is indirect and nonspecific to distinct cells or diseases. Various 
types of targeted nanoprobes have been developed for optical and molecular imaging 
such as super paramagnetic NPs; quantum dots and GNPs as cancer optical imaging 
probes (Ghosh et al., 2008). Molecular
 
imaging improves diagnostic
 
accuracy and 
sensitivity, by providing an in vivo analogue of immunocytochemistry
 
or in situ 
hybridization. It
 
seeks to enhance the conspicuity of microscopic pathologies
 
by 
targeting the molecular components or processes that represent
 
mechanisms of disease 
(Wickline et al., 2003; Barteneva and Vorobjev, 2010).  
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1.16.1. In vivo imaging of QDs 
Semiconductor QDs are emerging as a new class of fluorescent labels for biology and 
medicine and has become a topic of great research interest in both chemists and 
biologists. The broad absorption and narrow emission characteristics of the QDs make 
it possible to perform multicolor imaging with a single excitation source. The high 
fluorescence quantum yield of the QDs, their resistance to photo bleaching and their 
unique physical, chemical and optical properties make them good candidates for 
fluorescent tagging for in vivo molecular and cellular imaging (Gao et al., 2005; 
Kirchner et al., 2005; Li and Wu, 2010). The surface of QDs can be engineered or 
modified to improve QDs solubility, sensitivity, specificity and visualization in target 
tissue (Misra et al., 2010). Because visible QDs are more synthetically advanced, 
most animal imaging studies implementing QDs have used CdSe/ZnS QDs that emit 
visible light and a few recent studies started the use of near-infra red dots. Although 
still far from its mature stage, these studies have demonstrated the great performance 
and promise of QDs as fluorescent imaging agent in living animals (Kim et al., 2004 
and Cai et al., 2006). 
 
QDs have utility for a number of live cell imaging and detection applications, which 
can be done externally, but could also require the internalization of quantum dots by 
cells. Internalization of quantum dots for targeting and imaging applications has been 
achieved using a number of different strategies, including modifications to surface 
coatings for passive uptake and the use of specific molecules for mediated delivery 
(Zhu et al., 2008; Walling et al, 2009; Jaiswal et al., 2003). These altered surface 
coatings have been developed to increase the versatility and labelling efficiency of 
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quantum dots for live cells, both prokaryotes and eukaryotes (Walling et al., 2009). 
The various surface coatings enhance aqueous solubility, and provide varying 
functional groups for conjugation to antibodies, peptides, and other biomolecules, and 
reduced nonspecific binding to the cell surface (Bruchez et al., 1998). Other 
improvements to cellular imaging involve variations to the core composition for 
decreased cytotoxicity and increased biocompatibility (Walling et al., 2009). The 
ability to internalize quantum dot conjugates, along with the increased multiplexing 
capabilities, offers a major advancement in time- and cost-effectiveness over single-
color experiments. Ultimately, these advantages will contribute to the detection of 
various cell proteins or other components of heterogeneous tumor or tissue samples 
(Xing and Rao, 2008). 
 
1.17. The in vivo imaging techniques 
 
The in vivo imaging system is an optical imaging technique which looks deep into the 
tissues of living test subjects. Applications for in vivo imaging include studying 
biological signaling networks and pathways, gene expression, angiogenesis, and 
apoptosis. In order to take a picture of a tissue a centimetre or more into the animal, 
and accurately visualize the processes inside, it is necessary to use near-infrared light. 
The tools and technologies associated with the near-infrared window vary from 
standard fluorescence imaging tools. A number of CCD camera systems optimized for 
near-infrared imaging are now available (Shaffer, 2009). 
 An in vivo imager generally consists of a box for the animal, a near-infrared-capable 
CCD imaging system, and a computer interface. The animal box is designed to keep 
the animal comfortable and, typically, anaesthetized. Ports are included for 
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connecting supplies of anaesthetic gas, oxygen, and heat. Normally, optical imaging 
systems can only look at the surface of an object. However, in the near-infrared 
window of the spectrum, living tissues become "transparent" and the light source will 
penetrate the tissue and pick up fluorescence from near-infrared dye molecules 
Shaffer, 2009). 
 
1.17.1. The IVIS Luminar XR (Xenogen imaging system) 
The Xenogen IVIS imaging system is an advanced single-view 3D optical imaging 
system, design to improve quantitative outcomes of in vivo imaging. It is a sensitive 
imaging system that is easy to use for both fluorescent and bioluminescent imaging in 
vivo.  IVIS uses a large CCD camera, cooled to -90°C which gives the camera a very 
high sensitivity for deep image sources. The Xenogen IVIS® Lumina XR from 
Caliper Life Sciences is an affordable, highly sensitive imaging system that offers 
users the flexibility to image fluorescent and/or bioluminescent reporters both in vivo 
and in vitro. 
 It relies on Xenogen‟s novel patented optical imaging technologies to facilitate non-
invasive longitudinal monitoring of disease progression, cell trafficking and gene 
expression patterns in living animals. This user-friendly system includes a light-tight 
imaging chamber with complete computer automation, and the Living Image® 
software package for image acquisition and analysis. The system includes premium 
animal handling features such as a heated sample shelf, gas anesthesia connections 
and manifold, and an optional full gas anesthesia system. The imager can 
accommodate the maximum of five rats which can be imaged simultaneously. For the 
advanced fluorescence imaging, IVIS imaging system has the capability to use either 
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trans-illumination or epi-illumination to elluminate in vivo fluorescence source. The 
instrument is equipped with 10 narrow band excitation filters and 18 narrow band 
emission filter that assists in significantly reducing autofluorescence by the spectral 
scanning of filter and the use of spectral unmixing algorithms (Shaffer, 2009). The 
IVIS Lumina XR as indicated in Figure1.12.  
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Figure 1.12. The IVIS Luminar XR, imaging system 
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1.18. Application of nanotechnology in obesity 
 
Vascular targeting can be done both in vitro and in vivo. For the interest, the in vivo 
phage display method is a method for studying interactions between receptors 
expressed preferentially in an organ or tissue of interest and their corresponding 
ligands (Kolonin et al., 2004).  Kolonin and his coworkers screened the phage display 
library in the discovery of the synthetic peptide motifs (sequence CKGGRAKDC), 
which was then named adipose homing peptide (AHP). The AHP was found to be a 
vascular targeting peptide that homes to the white fat vasculature in obese leptin-
deficient (Lep 
ob/ob
) mice. This peptide motif was found to associates with prohibitin, a 
(PHB) multifunctional membrane protein and establish PHB as a vascular marker of 
adipose tissue. Kolonin further showed that by targeting the proapoptotic peptide to 
PHB in the adipose vasculature caused ablation of white fat (Kolonin et al., 2004).  
 
Because obesity is connected with WAT expansion, targeting the WAT will be a 
better approach for obesity treatment. Furthermore, obesity management is associated 
with side effects; therefore, a need still exists, to develop a better strategy which will 
be used in the treatment of obesity, nanotechnology can be considered as a new field 
of science that involves research and technology development to modify obesity 
treatment.  
 
Various nanoparticle functionalized with different biomolecules have been used due 
to their versatility, ease of chemical synthesis and less toxicity, because of this 
advantages and its safety it can therefore, hold effective role. Developing 
nanotechnology based approach, combined with the synthetic peptide motifs, 
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CKGGRAKDC, together with an anti-obesity drug will be a better way to target WAT 
vasculature. This will limit the problem of untargeted delivery which results in side 
effects and toxicity. Target-specific drug therapy and methods for early diagnosis of 
pathologies are the priority research areas in which nanotechnology would play a vital 
part (Misra et al., 2010).  
 
1.19. Problem statement 
 
Nanotechnology has been used in cancer research for drug delivery, cell detection and 
imaging (Atlanta, 2005; Lira et al., 2012). Recent studies suggest that physical 
characteristics of GNPs and QDs continue to be refined to further their utility. 
Synthetic methods, including conjugation and aqueous solubilisation steps, are critical 
in maximizing their properties for broader use. To the best of our knowledge the use 
of AHP functionalized QDs and GNPs as imaging and drug delivery agents in 
targeting the WAT vasculature of Wistar rats for obesity reversal has not been 
investigated before. Therefore this study will focus on the development of 
nanotechnology-based drug delivery using AHP functionalized GNPs, and imaging 
using AHP functionalized QDs in targeting the WAT vasculature of lean and obese 
male Wistar rats. 
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1.20. Aim and objectives of the study 
 
Aim of the study is to develop nanotechnology-based drug delivery and imaging 
system to the WAT vasculature of the male Wistar rats.  
 
Objectives: 
 To use biocompatible GNPs and QD625 functionalized with AHP to 
specifically target the WAT vasculature. 
 To test the use of AHP-GNPs and AHP-QDs as delivery and imaging agents to 
the WAT vasculature of obesity induced Wistar rats model, both in vitro and in 
vivo.  
 To isolate endothelial cells from the stromal vascular fraction of rats WAT, for 
ex vivo studies. 
 To functionalize AHP-GNPs with an anti-obesity drug (GA); (AHP-GNPs-
GA) and test for cytotoxicity and apoptotic effects in vitro. 
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1.21. Hypothesis 
 
The AHP-functionalized GNPs and QDs will specifically target the WAT vasculature; 
while a drug-loaded AHP functionalized GNPs (AHP-GA-GNPs) target and deliver 
the drug inside the cells.  
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CHAPTER 2 
2. Materials and Methods 
2.1. Materials: General Chemicals and Suppliers 
All chemicals used in the study and their suppliers are listed in Table 2.1 
Table 2.1. General chemicals and suppliers 
 
Chemical                                                                                                        Supplier                                                                                          
0.4 % Trypan Blue Solution                                   Invitrogen 
1X PBS, pH 7.2                                                                              Invitrogen                                                                                   
2.5 % Trypsin                                                                                       Gibco
6x orange DNA loading dye                      Fermentas 
AHD- FITC                                                                            Anaspec 
Alexa-flour Anti-rabbit 647 IgG (H+L)              Invitrogen 
Anti-Prohibitin antibodies                      Biolegend 
Biotin -AHP (AHP, CKGGRAKDC) Anaspec 
BSA  Seravac 
Cell culture media and reagents  Roche/ Lonza Diagnostics 
Cell proliferation Reagent WST-1                                                     Roche  
Collagenase from Clostridium histolyticum   Sigma 
DAPI(4,6-Diaminidine-2-phenylindoledihydrochloride)   Sigma 
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Dimethyl sulphoxide (DMSO) Sigma 
Dynabeads® CD31 Endothelial cells Invitrogen 
Ethanol 99.9 %   Kimix  
Fluoroshield   Sigma    
Foetal bovine serum (FBS) Lonza  
Gallic acid  
Gold NPs, streptavidin conjugate  
Sigma-Aldrich 
Mintek 
Hydrochloric acid (HCl)                                                                              Merck
Mitotracker  Invitrogen      
Nitric acid (HNO3)                                                                                          Merck 
Paraformaldehyde  Sigma-Aldrich 
Penicillin-Streptomycin                                                                                        Lonza                                                                                            
Quantum dots, streptavidin conjugate 625nm Invitrogen 
Agarose                                                                                      Lonza                                                                                          
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Table 2.2. Biochemical assay, kits and supplier 
 
Glucose (GO) assay kit                                                                    Sigma
Mercodia ultrasensitive Rat insulin ELISA kit                                        Mercodia developing diagnostic 
NEFA C kit                                                                                         Wako 
 
 
Table 2.3. Stock solutions and buffers. 
 
Stock solution /Buffer   Composition 
 
4 % Paraformaldehyde                                 
 
4 g Paraformaldehyde in 100 mL PBS 
10X  PBS: 80 g NaCl, 2 g KCl, 14.24 g Na2HPO4.2H2O, 2 g 
KH2PO4 in dH2O 
10x TBE                                        0.9 M Tris, 0.89 M boric acid, 25 mM EDTA, pH 
8.3 
Aqua regia 3:1 (V/V) HCl: HNO3 
Collagenase buffer  
 
40 ml PBS, 1 % BSA and 2 mg/ml Collagenase 
filter sterilized                                    
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Table 2. 4. Tissue culture media 
 
Media                                                        Components 
 
Complete DMEM                        DMEM, 10 % FBS and 1 % penicillin-streptomycin 
 
 
Table 2.5. Cell lines, species, source and media used. 
 
Cell line  Species  Source  Media 
Caco-2 Human Epithelial Colorectal 
adenocarcinoma 
Complete DMEM 
MCF-7 Human Breast carcinoma Complete DMEM 
CHO  Chinese Hamster  Ovary Complete HamsF12 
KMST-6 Human Normal fetal 
fibroblast 
Complete DMEM 
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2.2. Methodology 
2.2.1. General tissue culture procedures 
 
Vials of frozen cells were stored within a -150 
o 
C freezer. The cells were thawed at 37
o
 C 
water bath by submerging the lower half of the vial in the water to thaw only until a small 
amount of ice remained in the vial. The vial was thereafter placed in a laminar flow 
cabinet. Using a paper towel moistened with 70 % alcohol, the outside of the vial was 
wiped and the lid was loosened. The cells were transferred into tissue culture flasks 
containing pre-warmed appropriate culture medium supplemented with 10 % FBS and 1 
% streptomycin - penicillin (Absher, 1973).  
 
The flasks were properly labelled with the name of cell line and date of culture and 
incubated at 37
º
C, 5 % CO2 humidified incubator overnight. The following day the cells 
were inspected using inverted light microscope. Media was changed and cells were 
incubated for a further 24 hrs. When the cells reached confluency, they were washed once 
with 1X PBS and trypsinized with 0.125 % trypsin. Upon addition of trypsin, the cells 
were incubated for 5 to 10 minutes at 37
º
C. The cells were examined under light inverted 
microscope to monitor the detachment and floating of the cells. If they were not detached, 
the flask was gently tapped on the side until the cells were completely detached. Trypsin 
was inhibited by addition of complete media. The cells were centrifuged at 300 rpm for 3 
minutes and resuspended in trypsin free complete media. 
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2.2.2. Cryo-preservation of cell lines 
 
Cells were maintained in an incubator at 37
 º
C in 5 % CO2. They were monitored using 
an inverted microscope to assess the degree of cell density. Once the cells reached the 
required confluency and that they were free from bacterial or fungal contamination, they 
were washed with PBS and trypsinized as above. Trypsinization was stopped by the 
addition of 1ml complete medium. Cells were recovered by aspiration and transferred 
into a centrifuge tube. The tube was centrifuged for 3 minutes at 300 rpm in a bench top 
centrifuge. The supernatant was discarded and cell pellet was re-suspended in a solution 
of 90 % FBS and 10 % DMSO.  
 
A small aliquot of cells (100 - 200 μl) was removed and a cell viability count was 
performed as indicated in section 2.2.3. If the cell viability was in excess of 90 % the 
cells were frozen, if not the cells were discarded and a new culture was grown. This was 
done so as to achieve a good recovery after freezing. Cryo-vials were labelled with date 
of freezing, name of cell line, media in which the cell line was grown and the name of the 
person freezing the cells. The cells were then aliquoted into 1ml aliquots in the labelled 
cryo-vials at a concentration of 2.4x10
6
 cells per ml and were frozen at -150
o
 C. Before 
freezing, another aliquot of 50 - 100 μl was removed from the tube and cultured as a 
quality control to assess if the vials being frozen were free from contamination. The cells 
for quality control were grown for 24 - 48 hrs. If the cells were found to be contaminated, 
the vials were withdrawn from the freezer and discarded. 
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2.2.3. Cell count 
 
Under sterile conditions, 20-50 µl of the cell suspension was removed and mixed with an 
equal volume of Trypan Blue in a 0.6 ml Eppendorf tube and mixed by gentle pipetting. 
The countess chamber slides were properly filled with 10 µl of the sample without 
overfilling or under filling. The cells were then counted using the Countess® Automated 
Cell Counter (Invitrogen). 
 
2.3. In vitro Binding studies  
 
The 10
6
 cells/mL of Caco-2 cells, MCF-7, CHO and KMST-6 were cultured on cover 
slips in a 6 well plate for 24 hrs. The coverslips were removed and incubated at 25 ˚C 
with 20 µl of 4 % paraformaldehyde to fix the cells for 10 minutes. The cells where then 
washed with PBS to remove the paraformaldehyde. The cells were then incubated with 
the NPs for 1 hr at RT. Thereafter, the cells were washed three times with 1x PBS. The 
coverslip were placed upside down on a slide containing the mounting media 
(fluoroshield). The slides were viewed under the fluorescent microscope using DAPI, 
FITC and DsRed filters. The results were analyzed using Axio vision software.  
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2.4. Cytotoxicity and Cell viability studies 
2.4.1. Cell viability using WST-1 assay 
 
The cell viability test was determined using WST-1 according to reported protocols 
(Ngamwongsatit et al., 2008 and Yin et al., 2013) with some minor modification. In 
brief, the 2x10
5 
cells/mL
 
of Caco-2 cells were cultured in a 96 well plate for 24 hrs. The 
cells were then treated with different concentration of the NPs in complete media and 
then incubated for 24 hrs. Thereafter, the old media were removed and replaced with 
fresh media. The 10 µl of WST-1 was added to each well and incubated for 2 hrs at 37
 º
C. 
The Abs was measured by a POLAR star microplate reader at 430 nm with a reference 
wavelength at 620 nm. All experiments were done in triplicate and the relative cell 
viability was expressed as a percentage relative to the untreated control cells. The results 
were analyzed using a formula indicated below: 
 
 % viability = OD treated- OD blank / OD control - OD blank X 100 
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Figure 2. 1. Schematic procedure representing WST-1 cell viability assay 
 
 
 
 
 
 
 
 
 
Seed and 
culture cells 
Incubate with 
NPs  
Add WST-1 and 
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2.5. Quantification of cellular uptake of NPs 
 
The cellular uptake was determined following the methods described by Kumar et al., 
2012; Reuveni et al., 2011) with some minor modification. Briefly, the 5x10
5
 cells/mL of 
Caco-2 cells were cultured in a 12 well plate for 24 hrs. The cells were then treated with 
different concentration of the NPs and further incubated for 24 hrs. Thereafter, the cells 
were trypsinized with 1X trypsin and cell pellet were washed twice with PBS to remove 
any unbound NPs. The pellets was resuspended in 2 ml of aqua regia (HCl: HNO3, (3:1) 
and were digested at 90
º
C oven for 2 hrs, the digested sample were diluted with 2 % 
HNO3 to a final volume of 10 ml. The samples were analyzed using Inductive Coupled 
Plasma Optical Emission Spectroscopy (ICP-OES) by Ms Ilsie Wells at the Department 
of Chemistry, University of the Western Cape (UWC). The amount of NPs was 
calculated based on the concentration of cadmium (Cd) or gold (Au) found in the sample, 
thus using Cd and Au as standards. The results were expressed as percentage treated 
dose, using the formula below: 
 
For Gold (Au) quantitation 
 % Au = Concentration of Au detected / Concentration of Initial amount of Au x 1000 
 
For Cadmium (Cd) quantitation 
 % Cd = Concentration of Cd detected / Concentration of Initial amount of Cd x 1000 
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2.6. Agarose gel electrophoresis  
 
Gels were prepared by boiling the appropriate mass of agarose in 1x TBE, cooled to 50
º
C 
and left to solidify at room temperature. Then fifteen (15) µl of the sample was mixed 
with 3 µl volumes of 6x DNA loading buffer and loaded into the gel. The 1x TBE was 
used in the electrophoresis of the gel. The gels were run at 115V for 20 minutes at room 
temperature. Gels were viewed and photographed using UVP imaging system. This was 
done to confirm the functionalization of the NPs.  
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2.7. Nanotechnology 
2.7.1. Synthesis, functionalization and characterization of Gold NPs (GNPs) 
Streptavidin conjugate GNPs 520nm were synthesized and functionalized by the 
Advanced Material Division (Mintek, South Africa). They were functionalized with a 
biotinylated (Biotin-Tyr-Cys-Lys-Gly-Arg-Ala-Lys-Asp-Cys-OH), Adipose Homing 
Peptide (AHP, Anaspec) and polyethylene glycol (PEG). Both functionalized (AHP-
GNPs) and unfunctionalized GNPs (GNPs) were characterized using UV-VIS 
spectroscopy, Transmission Electron Microscopy (TEM) and agarose gel electrophoresis. 
2.7.2. Functionalization and characterization of Quantum dots (QDs) 
Streptavidin conjugate QDs emitting at 625nm were purchased from Invitrogen. QDs 
were functionalized with biotinylated AHP (Biotin-Tyr-Cys-Lys-Gly-Arg-Ala-Lys-Asp-
Cys-OH, Anaspec). Briefly, 5 µl of 1µM streptavidin QDs was mixed with 4 µl of 25 µM 
biotin AHP, and 1X PBS (pH 7.4) was added to make a final volume of 100 µl. Both 
functionalized (AHP-QDs) and unfunctionalized QDs (QD625) were characterized using 
agarose gel electrophoresis and HORIBA Nanolog FL3-22 Triax. This was done 
following the procedure described by Yang et al., 2010, with some minor modification. 
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2.7.3. Synthesis, functionalization and characterization of AHP-GA-GNPs 
  
The Gallic acid (GA) was used as a drug in this study. It was prepared by dissolving the 
appropriate amount in grams in PBS, pH 7.4. The GA was filter sterilized using 0.22 µm 
filters and was kept at 4
º
C until use. In this study, GA was conjugated to AHP 
functionalized GNPs through (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
chemistry, to form a peptide-targeted, drug-loaded GNPs (AHP-GA-GNPs).  
  
The AHP-GA-GNPs were synthesized and functionalized by the Advanced Material 
Division (Mintek-South Africa) according to the procedure represented in Figure 2.2. The 
functionalized AHP-GA-GNPs were characterized using UV-vis spectroscopy and 
transmission electron microscopy (TEM). 
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Figure 2.2. Schematic representation of the synthesis of AHP-GA-GNPs.
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2.8. Quantitative Cellular uptake of GNPs, QDs and GA 
 
The cellular uptake experiment was determined following the methods described by 
(Kumar et al., 2012 and Reuveni et al., 2011) with some modification. Briefly, the 5x10
5
 
of Caco-2 cells were cultured in a 12 well plate for 24 hrs. The cells were then treated 
with QDs, AHP-QDs, GNPs, AHP-GNPs, GA or AHP-GA-GNPs for 24 hrs. The cellular 
uptake was determined using ICP-OES or ICP-MS, as described in Section 2.5. 
  
2.9. Cell viability test on GA, GNPs, QDs and AHP 
 
The cell viability test was determined using WST-1 following the methods described by 
Ngamwongsatit et al., 2008, Maurya et al., 2011, and Yin et al., 2013, with some 
modification. In brief, the 2x10
5 
of Caco-2 cells were cultured in a 96 well plate for 24 
hrs.  The cells were then treated with different concentration of either QDs; AHP-QDs, 
(0, 6.25, 12.5,25 nM), GNPs; AHP-GNPs (0, 1, 2, 4), GA (0, 12.5, 25, 50 nM), AHP-
GNPs-GA (0, 1, 2, 4 nM) or AHP (0, 6.25, 12.5, 25 nM) for either 24 or 48 hrs. The cell 
viability was determined using WST-1 as described in Section 2.41.  
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2.10. Determination of apoptosis by APOPercentage 
TM
  
 
Apoptosis assays involve detection and measurement of apoptosis in mammalian, 
anchorage-dependent cells during in vitro culture. The assay was done according to 
Meyer et al., (2008) protocol, with some minor modification. The assay uses a dye that is 
selectively imported by cells that are undergoing apoptosis. Necrotic cells cannot retain 
the dye and therefore are not stained. To determine the apoptotic effect of GA, the Caco-
2 cells (1x10
6 
cell/mL) were seeded in a 12 well plate for 24 hrs. The cells were then 
treated with 25 nm, GA, 2nm AHP-GA-GNPs and Cisplatin 10 µM (positive control) for 
24 hrs. The negative control cells remain untreated for 24 hrs. The cells were examined 
under microscope for morphological changes. They were then trypsinized and washed 
twice with PBS, and thereafter, resuspended in PBS. The 200 µl APOPercentage
TM
 dye 
in complete media (1:60 dilutions) was added to the tubes and cells were incubated for 30 
minutes at 37
º
C humidified CO2 incubator. The 500 µl of PBS was then added and spun 
for 5 minutes at 300 rpm. The cells were washed twice with PBS and resuspended in 400 
µl PBS. The cells were then acquired and analyzed on FACScan 
TM
 (Becton Dickson) 
instrument. Acquisition was done by setting forward scatter (FSC) and side scatter (SSC) 
on a scale dot plot. 
 
 The APOPercentage
TM
 (FL-3 channel) was measured against relative cell numbers.  
Negative control cells were used to set cells in the negative quadrant before all sample 
were acquired. Acquisition was done in Log mode. A minimum of 10,000 cells per 
sample were acquired and analyzed using CELL Quest PRO software (BD Biosciences), 
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by setting the non-stained (untreated) cells population in the first quadrant (10
1
) of the 
forward side scatter histogram dot plot and cells which appeared after 10
1 
and
 
in the 
second (10
2
) or third (10
3
) quadrant were regarded as APOPercentage
TM
 positive 
(apoptotic/necrotic). 
 
2.11. Determination of Caspase 3 activity 
 
Caspase 3 activation plays a major role in the execution of apoptosis. To determine 
whether GA-loaded GNPs activate Caspase 3 in Caco-2 cells, the cells (2.5x10
4 
cell/mL) 
were seeded in a 24-well culture plate and were incubated at 37
 º
C in a humidified 5% 
CO2 incubator for 24 hrs. The assay was done following the work done by Budihardjo 
and colliques (1999) with some modification. The cells were then treated with GA (25 
nM), AHP-GA-GNPs (2 nM) and Cisplatin (10 µM) (positive control) for 24hrs at 37
 º
C 
incubator. The negative control cells were untreated for 24 hrs. The cells were examined 
for morphological changes using an inverted light microscope. Cells were trypsinized as 
described in section 2.2.1. The pellet was washed twice with 500 µl cold PBS and 
resuspended in 0.5 ml Cytofix/CytopermTM, and then incubated on ice for 20 minutes.  
The cells were then spun in a bench top centrifuge at 300xg for 2 minutes. The
 
Cytofix/CytopermTM was then aspired and discarded. The pellets were washed twice with 
0.5ml Perm/WashTM buffer. Total number of samples was determined, and the amount of 
Perm/WashTM buffer and anti-active Caspase-3 Antibody were calculated so that each 
sample received 100 µl Perm/WashTM buffer and 20 µl anti-active Caspase 3 Antibody.  
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The cells were then incubated for 30 minutes at RT in the dark. At the end of the 
incubation period, the cells were washed twice with 1.0 ml Perm/WashTM buffer. The 
supernatant was discarded and the pellets were resuspended in 0.5ml Perm/WashTM 
buffer. The cells were acquired and analyzed on FASCcanTM FACScan
TM
 (Becton 
Dickson) instrument. Cell fluorescence was measured using dot plot, (by setting the 
forward scatter (FSC) and side scatter (SSC) to differentiate cell populations and cell 
debris. Active Caspase 3 FITC was measured against relative cell numbers. Negative 
control cells were used to set the cells in the negative quadrant before all samples were 
acquired. A minimum of 10,000 cells per sample were acquired and analyzed using 
CELL Quest PRO software (BD Biosciences). 
 
2.12. Ex vivo binding and cellular uptake studies  
2.12.1. Isolation of Endothelial cells (ECs) from WAT using Dynabeads®   
2.12.2. Digestion of WAT by collagenase method 
 
The 5 g of white adipose tissue (WAT) isolated from Epidydimal and Inguinal 
(subcutaneous) fat depots of the male Wistar rats, fed a high fat (HF) diet or chow control 
diet were weighed and rinsed in PBS. The tissues were minced in PBS using a sharp 
sterile scissor. The 1 % BSA and 1mg/ml collagenase prepared in PBS, was added to the 
minced tissue in a 200 ml conical flask and incubated at 37
º
C water bath until completely 
digested. Tubes were checked every 10 minutes. The homogenates were filtered through 
200 µm nylon filters to remove any large pieces of undigested tissue and were then kept 
at room temperature for 3-5 minutes to allow visible separation. The upper layer 
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(supernatant) which contained the adipocyte was discarded and the bottom layer (the 
microvascular fraction) was then filtered using 20 µm nylon filters. The filtrate was used 
for the isolation of the endothelial cells using Dynabeads® method. 
 
Dynabeads® CD31 are uniform, superparamagnetic polystyrene beads (4.5 μm diameter) 
coated with a mouse IgG1 monoclonal antibody specific for the CD31 cell surface 
antigen PECAM-1 (platelet endothelial cell adhesion molecule-1). The Dynabeads® were 
prepared by resuspending a vial of 25 µL with an equal amount of the buffer in a 2ml 
Eppendorf tubes. The tubes were placed in a magnet (DynaMag™-2 Magnet, Invitrogen) 
for one minute and the supernatant was discarded. The tubes were then removed from the 
magnet and were again mixed with equal amount of buffer as the initial volume of the 
Dynabeads. The dynabeads were then ready to be used, in the isolation of the ECs. The 
ECs was prepared by adding an appropriate amount of the Dynabeads® to a single 
suspension of the microvascular fraction. The tubes were then incubated for 20 minute at 
4
º
C with gently titling and rotation. The tubes were thereafter placed in a magnet for 2 
minutes. The supernatant was discarded and the beads bound endothelial cells were 
washed 3 times with PBS (equal amount with the initial dynabeads). The beads bound 
endothelial cells were counted using the Countess® Automated Cell Counter (Invitrogen) 
and then used for cellular uptake experiment. 
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2.12.3. Treatment of primary ECs with AHP functionalized QDs  
 
For the binding of AHP- QDs to primary cells, the isolated microvascular ECs from the 
inguinal and epididymal WAT of both lean and obese rats were incubated with 50 and 25 
nM concentration of AHP-functionalized and unfunctionalized QDs for 1hr at 37
º
C.  The 
cells were spun at 300 rpm for 3 minutes and the cell pellets were washed twice with 1X 
PBS and processed for ICP-OES as described in section 2.5.  
 
2.13. Caco-2 cells 
 
The Caco-2 cells are a continuous line of heterogeneous human epithelial colorectal 
adenocarcinoma cells. Although derived from a colon (large intestine) carcinoma, when 
cultured under specific conditions the cells become differentiated and polarized such that 
their phenotype, morphologically and functionally, resembles the enterocytes lining the 
small intestine. The Caco-2 cell line was used as an in vitro model in this study.  The 
choice of the cell line was based on presence of PHB which is expressed on the surface of 
this cell line (Sharma and Qadri, 2004).  
 
Caco-2 cells were grown in Dulbecco‟s modified Eagle‟s medium (DMEM) as described 
by Klein et al, 2009, supplemented with 10 % foetal bovine serum (FBS), 2 mM 
glutamine and antibiotics (2 % penicillin and streptomycin) under standard cell culture 
conditions (humidified incubator maintained at 37
º
C and 5 % carbon dioxide). Growing 
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cells were observed daily under a Nikon inverted light microscope to monitor confluency 
and contaminations. 
 
2.14. Indirect cellular binding of AHP using competitive displacement 
 
Caco-2 cells were used as in vitro model as described in section 2.9. The binding and 
internalization of AHP was determined at 4
º
C and 37
º
C, by flow cytometry (FACS) and 
fluorescence microscopy. 
 
2.14.1. Flow cytometer 
 
 Cells were seeded in a 24 well plates for 24hrs. They were then incubated with different 
concentrations of FITC-labelled AHP (AHP-FITC, 0-2 mM) at 4
º
C and 37
º
C for 1 hr. The 
cells were trypsinized for 5 minutes at 37
 º
C and centrifuged at 300 rpm for 5 minutes and 
the pellets were resuspended in 500 µl PBS, and the cells were analysed using 
FACScan
TM
 (Becton Dickson) flow cytometer. A minimum of 10,000 cells per sample 
were acquired and analysed using CELL Quest PRO software (BD Bioscience). 
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2.14.2. Fluorescence microscopy  
 
Cells were seeded on a cover slip in a 6 well plate. They were incubated with different 
concentrations of FITC-labelled AHP (AHP-FITC, 0 - 2 mM) at 4
º
C and 37
º
C for 1 hr. 
The cells were thereafter, fixed with 4 % paraformaldehyde for 15 minutes at both 4
º
C 
and 37
º
C. The cells were then washed twice with 1X PBS. The cover slip were removed, 
and placed upside down on a slide containing mounting media (flouroshield). The slides 
were viewed under fluorescence microscopy, using DAPI and FITC filters and results 
analysed under Axio vision software.  The specific binding was also examined by 
competitive binding with AHP-GNPs at 4
º
C and 37
º
C. In brief, the cells were incubated 
with 1mM AHP-FITC and 3nM AHP-GNPs at 4
º
C and 37
º
C for 1 hr. The cells were then 
prepared for flow cytometry and fluorescence microscopy as described above. 
 
2.15. Immunofluorescence labeling and localization of prohibitin 
 
The 10
6
 cells/mL were cultured on a cover slip in a 6 well plate for 24 hrs at 37
º
C. The 
cells were incubated with 1mM AHP-FITC for 24 hrs. They were washed twice with 1X 
PBS and fixed with cold methanol (methanol in Triton
R
 X-100) for 5 minutes at 4
º
C. The 
cells were then washed twice with PBS and incubated with PBS/BSA (0.5 % BSA in 
PBS) at room temperature (RT) and incubated for 30 minutes. They were then incubated 
with primary antibody; purified anti-prohibitin (1:10 dilution, diluted in PBS/BSA) for 1 
hr and thereafter washed twice with PBS and incubated with secondary antibody; donkey 
anti-rabbit-IgG-FITC, diluted as the primary antibody. The cells were washed twice with 
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PBS and the cover slips were transferred to the slide containing mounting media, and 
slides viewed under fluorescence microscopy using Texas Red filter. 
 
2.16. MitoTracker
®
 staining  
 
To label mitochondria, MCF-7 cells were simply incubated with MitoTracker
®
 Red. The 
10
6
 cells/mL were grown on coverslips in a 6 well plate for 24 hrs at 37 
º
C. The media 
was removed and cells were washed with PBS and trypsinized for 5 minutes at 37
º
C. 
They were then spun for 3 minutes at 300 rpm and washed twice with PBS. The cells 
were then stained with pre-warmed MitoTracker
®
 Red prepared in media and incubated 
at 37
º
C for 30 minutes. They were then washed twice with PBS and fixed with 4 % 
paraformaldehyde at 37
º
C for 15 minutes, and were again washed with PBS. The cells 
were thereafter, incubated with 0.1 % Triton
R
 X-100 in PBS for 10 minutes to 
permebialize the cells. The cells were rinsed with PBS and the coverslips were 
transferred to a slide containing mounting media and placed upside down. The slides 
were viewed under fluorescence microscopy and results analysed using Axio-vision 
software.  
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2.17. In vivo studies 
2.17.1. Animals and Ethics approval 
 
Twenty (20), 3 weeks male Wistar rats weighing 40-50 g were obtained from Medical 
Research Council (MRC) animal facility. All procedures involving animals were 
approved by the MRC Ethics Committee for Research on Animals (ECRA), ethics 
number:  03/10. The study was also recommended for approval to the University of the 
Western Cape (UWC) Senate‟s Research and International Relations Committee (RIRC) 
by UWC‟s Faculty of Natural Sciences RIRC, reference number: SCR IRC 2012/06/17. 
All rats were housed under a controlled temperature (22-25 
º
C), humidity (45-55 %), 
ventilation (15-20 cycle/hour) and a 12 hour photo-period. They were body weight 
matched and assigned to different groups. Four rats were housed per cage from the 
beginning of the study and throughout the obesity induction phase. The cages were 
provided with bedding material and a black perspex nest box. The cages were changed 
weekly. Fresh food (HF patties and Chow) and water were provided ad libitum daily. 
2.18.2. Grouping of animals and induction of obesity 
The 20 male Wistar rats were divided into two groups: one group was the rats fed on 
standard chow (n= 4) and other was rats fed on high fat diet (n= 16) as indicated in 
section 2.13.3, to induce obesity. The rats were monitored daily and their body weights 
were measured twice per week.  
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2.18.3. Preparation of Lard high fat (HF) Diet  
 
The lard high fat diet was prepared using lard, sugar and chow as indicated in Table 2.6. 
The lard was melted and sugar and chow were weighed. All the ingredients were mixed 
in a bowl with the addition of warm water. They were rolled on a tray and cut into cubes 
using a sharp knife or pizza cutter and was kept at 4
º
C until set. The diet was then divided 
into plastic bags and stored at -20
º
C until use.  
 
Table 2. 6. Ingredients for Lard HF diet preparation 
 
 
 
 
 
 
 
 
Ingredients Amount (g)  Percentage ( %) 
    Chow    1800     72  
    Lard     600        24  
    Sugar     100        4  
    Water    1 liter  
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2.19. Treatment of rats  
2.19.1. General experimental design 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Schematic diagram representing experimental design used for the in vivo studies 
 
 
 
Control-HF 
(GNPs; QD625) 
n = 4 
 
 
 
 
 
 
 
 
 
AHD-GNPs 
n = 4 
AHD-QDs 
n = 4 
Control, chow 
n = 4 
              In vivo imaging (Xenogen imaging system over 2 days 
                    Termination and collection of blood and tissue over 2 days 
- Inject intravenously 
20 Rats Male Wistar rats 
4 rats CHOW, 12 weeks   16 rats – HF, 12 weeks 
 - Remove DR rats (n = 4)  
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2.19.2. Experimental procedure: Treatment of animal with nanoparticles 
Twenty male Wistar rats were used in the study. Four rats were fed CHOW (n = 4), and 
sixteen rats were fed a high fat diet (HF) diet (n = 16) for 12 weeks ad libitum. The body 
weights were measured twice per week.  After 16 weeks on HF diet, diet resistance (DR) 
rats were removed from the study, and the 12 rats divided into three groups (n = 4 per 
group). Imaging and termination by exsanguinations were performed over two days, 8 
rats per day. On the day, eight rats (2 at a time) were anesthetized by nasal inhalation of 
halothane (initiation at 5 %, and maintenance at 1 % in oxygen at 1L/min flow rate). Rats 
were injected intravenously through the tail vein with 200 µl of PBS (CHOW and HF 
control groups), 200 µl of AHP functionalized GNPs (AHP-GNPs group), or 
unfunctionalized GNPs dissolved in PBS and 200 µl of AHP functionalized QDs (AHP-
QDs group) or unfunctionalized QDs (QD625) dissolved in PBS and kept for 24 hrs.  
 
2.19.3. Termination of animals 
 
After 24 hrs, rats were terminated via exsanguination under anaesthesia with an ip 
injection with sodium pentobarbital, 30 mg/kg body weight. Bloods were collected 
through hepatic vein and tissues (adipose tissues, liver, kidney, lungs, spleen, stomach, 
brain, heart, pancreas, testes, and adrenals) were dissected, weighed and imaged using 
IVIS® Lumina XR (Caliper Life Sciences) as shown in Figure 2.4. The adipose tissue 
and organs were snap-frozen in liquid nitrogen to be used for analysis of any effects 
inflicted by the therapy using molecular and cellular techniques. The tissues and organs 
were stored at -80
º
C until analysis. The blood was stored in the refrigerator at 4
º
C.  
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The serum samples were prepared followed the methods described by Yen and Hsu, 
(2007), with some minor modification. The 10ml blood samples were collected from both 
lean and obese rats through hepatic vein. The bloods were centrifuge at 12000 rpm for 10 
minutes, the resulting supernatant, designated serum, was carefully removed using a 
micropipette and was transferred to 2 ml tubes. The serum was then stored at -80
º
C fridge 
for later use. 
 
2.20. Tissue biodistribution of gold and ccadmium  
 
The tissue and organs were processed according to the work done by Sonavane et al., 
2008 with some modifications. The tissues and organs were cut into small pieces (1g 
each), homogenized and completely lysed in 2ml of aqua regia in a screw cap glass 
bottles. The homogenate was digested in a 70
º
C oven for 24 - 48 hrs. They were then 
redissolved in 2ml of 2 % HCl and sonicated for 2 - 5 minute or until resuspended. The 
resultant samples were diluted in 2 % HNO3 and analyzed by ICP-OES. Cadmium (Cd) 
and gold (Au) were used as standards to quantify the concentration of QDs and GNPs in 
the tissue samples. 
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  Figure 2.4. The Ex vivo tissue imaging using IVIS® Lumina XR (Xenogen imaging system) 
 
 
 
 
 
 
 
 
Chapter 2                                                                                                                  Methodology 
99 
 
2.21. Biochemical assays 
2.21.1. Insulin, non-esterified fatty acid (NEFA) and glucose measurements 
 
The Glucose oxidase assay, NEFA C and Rats Insulin Elisa kits were used to measure the 
serum concentration of glucose, free fatty acid and insulin. Serum samples were obtained 
from lean and obese Wistar rats, treated with GNPs, AHP-GNPs, GDs, AHP-QDs and 
PBS. 
 
2.21.2. Quantitative determination of Insulin concentration  
 
The concentration of insulin was measured using Mercodia Ultrasensitive Rat Insulin 
Elisa kit, (Mercodia developing diagnostics, 2010). Samples were measured in triplicate. 
The 25 µl of the serum samples, calibrators and 100 µl of the enzyme conjugate were 
added and mixed in a 96 well plate. The plate was incubated at room temperature (25
º
C) 
for 2 hrs with shaking. The plate was thereafter washed 6 times, with 300 µl wash buffer 
using an automatic plate washer. The 200 µl substrate TMB was then added to each well 
and incubated for 15 minutes at 25
º
C. The 50 µl of stop solution was added to each well 
to stop the reaction. The plate was shaken for 15 sec and the optical density or Abs was 
taken at 450 nm using a POLAR STAR plate reader. The concentration of insulin in µg/L 
was determined from the standard curve generated from calibrators.  
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2.21.3. Quantitative determination of NEFA concentration  
 
The Wako NEFA C test kit was used to measure the concentration of free fatty acid from 
serum samples. The samples were measured in triplicate, according to the manufacturer 
protocol, (Wako). The 20 µl of the serum sample, standard, reagent blank and 500 µl of 
colour reagent A were mixed in a 0.6 eppendorf tube, and incubated at 37
º
C for 10 
minutes. The 1000 µl of the colour reagent B was added to all tubes and were further 
incubated for another 10 minutes. The tubes were thereafter mixed and 200 µl of each 
sample were transferred to a 96 well plate. The NEFA concentration were obtained by 
measuring Abs of the blue purple colour at 550 nm using Polar star plate reader. The 
samples were measured in triplicate. The results were determined using the formula 
below: 
 
Free fatty acid (mg/dL) = Abs (sample) x Conc (standard) (mg/dL) / Abs (standard) 
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2.21.4. Quantitative determination of glucose concentration  
 
In this experiment, the glucose concentrations from lean and obese rats were determined 
using glucose oxidase assay kit, (Sigma Aldrich). Briefly, 50 µl of serum sample, 5 µl 
standards and 100 µl of assay reagent were added to 96 well plates and were incubated at 
37
º
C for 30 min. Then 100 µl of H
2
SO
4
 was added to stop the reaction and the plate was 
further incubated for 5 minute. The glucose concentrations were obtained by measuring 
the Abs or intensity of the pink color at the wavelength of 540 nm. The samples were 
measured in triplicates using a POLAR STAR plate reader. The glucose concentration 
was determined using the formula:  
 
Glucose (mg) = Abs (sample) x (mg glucose in standard)/ Abs (standard) 
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2.22. Statistical Analysis of data 
The different parameter were analysed using one way Anova, to assess the different 
between samples used for in vitro experiments. Student‟s t-test was used to compare the 
differences between two groups used for in vivo experiments. All the analyses were 
performed using Graph pad prism 5 statistical package. The samples were considered 
statistically significant when p<0.05  
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CHAPTER 3 
3. Results and discussion 
3.1. Synthesis, functionalization and characterization of gold NPs (GNPs) 
 
The AHP-functionalized GNPs (AHP-GNPs) were synthesized at Mintek, as described in 
section 2.7.1. To confirm the functionalization of GNPs, agarose gel electrophoresis (A) 
and UV-Vis spectroscopy (B) were performed (Figure 3.1) before (GNPs) and after 
functionalization (AHP-GNPs). The gel electrophoresis (Figure 3.1.A) showed that the 
functionalized GNPs migrate slower in the gel than unfunctionalized GNPs (GNPs) while 
UV-Vis spectrum (Figure 3.1.B) showed the functionalized GNPs has a higher absorption 
peak as compared to unfunctionalized GNPs and Transmission electron microscopy 
(TEM) analysis (Figure 3.1.C) shows that the functionalized GNPs are spherical in shape 
and well dispersed. 
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Figure 3. 1. Characterisation of GNPs and AHP-GNPs by agarose gel electrophoresis (A), UV-vis 
spectroscopy (B) and TEM (C).  
 
 
 
 
 
 
100nm 
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3.2. Synthesis, functionalization and characterization of AHP-GA-GNPs 
 
The nanoparticles functionalized with AHP and gallic acid (GA) was also synthesized at 
Mintek. The nanoparticles were characterized using TEM and UV-Vis spectroscopy. As 
indicated in Figure 3.2, the particles were found to be uniform and spherical in shape as 
determined by TEM and UV-Vis spectrum indicates the maximum absorption peak of 
530 nm. 
 
 
 
 
 
 
 
 
Figure 3. 2. The TEM (A) and UV-VIS spectrum (B) analysis of 14nm AHP-GA-GNPs. 
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3.3. Functionalization and characterization of Quantum dots (QDs) and AHP-QDs 
 
The QD625 (Invitrogen) were functionalized with AHP as described in section 2.7.2. To 
confirm the functionalization of QDs with AHP (AHP-QDs), agarose gel electrophoresis 
was performed. As shown in Figure 3.3 (B), AHP functionalized QDs migrate slower in 
the gel as compared to unfunctionalized QDs. Figure 3.3 (A) shows the fluorescence of 
QD625 and AHP-QDs, under UV (365 nm ) light, using UVP imaging system. The 
HORIBA Nanolog FL3-22 Triax was also used to confirm the photoluminescence of the 
QDs. The emission wavelength for both QD625 and AHP-QDs was 625 nm as indicated 
in Figure 3.4. 
 
 
 
 
 
 
 
 
Figure 3.3. Fluorescence images of QD625 and AHP-QDs.      
 
Image (A), represent the fluorescence of QD625 and AHP-QDs before gel electrophoresis while image (B), 
show agarose gel electrophoresis of both QD625 and AHP-QDs.  
       QD625                AHP-QDs      QD625                     AHP-QDs 
A B 
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Figure 3.4. Photoluminescence (PL) spectra of QD625 and AHP-QDs.  
The spectrum were measured using HORIBA Nanolog FL3-22 Triax 
 
 
 
 
 
 
 
 
Chapter 3                                                                                                   Results: In vitro studies 
108 
 
3.2. Immunofluorescence labeling and localization of prohibitin 
 
MCF-7 is a breast cancer cell line that expresses prohibitin (PHB), (Rastogi et al., 2006), 
a multifunctional membrane protein receptor. PHB is expressed on the plasma membrane 
and the mitochondria. To investigate the localization of PHB in MCF-7 cells, the cells 
were stained with Anti-PHB-FITC (Figure 3.5.A) and the Mitotracker
R
 Red (Figure 
3.5.B) and analysed by fluorescence microscopy.  
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Figure 3. 5. Fluorescence image showing intracellular localization of prohibitin in the mitochondria 
of MCF-7 cells.  
 
Cells were stained with anti-PHB-FITC (A) and Mitotracker Red (B). Images were taken using 
fluorescence microscopy at 100 x magnification. The scale bar is 10 µm 
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To further confirm the presence and expression of PHB on MCF-7, the cells were stained 
with Rhodamine conjugated anti-prohibitin antibody (Anti-PHB-Rhodamine) and DAPI. 
The Anti-PHB-Rhodamine staining showed the presence of PHB, and that PHB localize 
in the nucleus of MCF-7 cells. This is shown in Figure 3.6, which shows fluorescence 
image of the nucleus under DAPI (A), Rhodamine (B) and the overlay (C), indicating 
Rhodamine staining the nucleus of the cells 
 
 
 
Figure 3.6. Fluorescence image showing intracellular localization of prohibitin in the nucleus of 
MCF-7. 
 
The cells stained with DAPI (A), showing nucleus of the cells, anti-PHB Rhodamine (B), and (C), the 
overlay of A and B. Images were taken using fluorescence microscopy at 100 x magnification. The scale 
bar is 10 µm. 
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3.3. Investigating binding and localization of AHP-QDs to PHB expressing cells 
 
3.3.1. Binding to MCF-7 
 
To confirm the binding and localization of AHP-QDs in MCF-7 cells, the cells were 
incubated with either QD625 or AHP-QDs and were imaged using fluorescence 
microscopy. It is shown in Figure 3.7 that the AHP-QDs localized in the nucleus of the 
MCF-7 cells.  
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Figure 3. 7. Fluorescence images of MCF-7 cells stained with either QD625 (A) or AHP-QDs (B).  
 
MCF-7 cells were exposed to either QD625 (A) or AHP-QDs (B) for 1 hr. The QD625 fluorescence 
observed clearly in cells exposed to AHP-QDs (B). Images were taken using fluorescence microscopy at 
100x magnification. The scale bar is 10 µm. 
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3.3.2. Binding to Caco-2 cells 
Caco-2 is a colon cancer cell line that was shown to expresses PHB (Sharma and Qadri, 
2004). The cells were used to confirm the binding of AHP-QDs to PHB expressing cells. 
To confirm the binding and localization of AHP-QDs on cells, the Caco-2 was treated 
with either QD625 or AHP-QDs. The images were taken using fluorescence microscopy. 
The cells treated with AHP-QDs showed binding to Caco-2 cells, hence red fluorescence 
while QD625 did not show any fluorescence. This is shown in Figure 3.8. 
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Figure 3. 8. Fluorescence images of Caco-2 cells, treated with AHP-QDs and QD625. 
 
Caco-2 cells were exposed to either QD625 (A) or AHP-QDs (B) for 1 hr. The QD625 fluorescence 
observed in cells exposed to AHP-QDs (B). Images were taken using fluorescence microscopy at 100x 
magnification. The scale bar is 10 µm. 
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3.4. Investigating the Binding of AHP-QDs to non-PHB expressing cells 
 
The binding of AHP-QDs was also investigated using non-PHB expressing cells. These 
includes: non-cancerous cell lines, CHO (Chinese-Hamster-Ovarian) and KMST-6 
(Human-normal fetal fibroblast). These cell lines were used as negative controls. The 
cells were treated with either QD625 or AHP-QDs. No QDs fluorescence was observed 
to all the cells treated with either AHP-QDs or QD625 as shown in Figure 3.9. This is 
because the cells don‟t express PHB, hence no binding, therefore no fluorescence of QDs. 
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Figure 3. 9. Fluorescence images of CHO and KMST-6 cells treated with AHP-QDs and QD625. 
 
Caco-2 cells were exposed to either QD625 (A) or AHP-QDs (B) for 1 hr. The QD625 fluorescence 
observed in cells exposed to AHP-QDs (B).  (1), represents CHO cells and (11) KMST-6 cells. Images 
were taken using fluorescence microscopy at 100x magnification. The scale bar is 10 µm. 
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3.5. Quantitative analysis of AHP binding to Caco-2 cells 
 
To quantitate the binding of AHP to Caco-2 cells (PHB-expressing cells), the cells were 
incubated with increasing concentrations (0.01-2mM) of AHP-FITC and the fluorescence 
intensity was measured by flow cytometer. A dose dependent increase in the fluorescence 
intensity was observed. Figure 3.10 demonstrating a dose dependent increase in the 
binding of AHP-FITC to the cells. 
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Figure 3. 10. Quantification of cellular binding of AHP-FITC to Caco-2 cells.  
Caco-2 cells were exposed to increasing concentration of FITC-labeled AHP (AHP-FITC) for 1 hr at 37
º
C. 
Fluorescence intensity was measured using flow cytometry.          
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3.5.1. Direct binding of AHP to primary endothelial cells 
To examine the specificity of the binding of AHP to primary endothelial cells (ECs), ECs 
were isolated from the WAT of lean and obese Wistar rats, and incubated with 
unfunctionalized and AHP functionalized QDs. Binding specificity of AHP-QDs was 
measured by ICP-OES using cadmium as a standard. The cadmium concentrations in ECs 
from lean and obese rats were lower for cells exposed to QD625 (Figure 3.11). ECs from 
obese rats also contained higher concentrations of cadmium compared to ECs from lean 
rats. 
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Figure 3. 11. Quantification of AHP-QDs binding to microvascular endothelial cells. 
 The ECs from subcutaneous (SQ) and epididymal (Epi) WAT were exposed to either unfunctionalized or 
AHP-functionalized QDs for 1 hr at 37
º
C. Bar graph show concentration of cadmium (Cd), as a % of 
treatment dose present in each sample as determined by ICP-OES analysis. 
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3.5.2. Indirect binding of AHP 
To determine whether the binding of AHP-FITC was specific and temperature dependent, 
Caco-2 cells were incubated at 4 and 37
º
C, in the presence or absence of AHP-GNPs 
which served as a competitor for AHP-FITC. As shown by flow cytometry (Figure 3.12). 
The binding of AHP-FITC to Caco-2 cells was lower at 4
º
C. Also, incubation of cells 
with AHP-FITC in the presence of AHP-GNPs prevented the binding of AHP-FITC to 
Caco-2 cells. These data suggest that the mechanism for the intracellular uptake was 
mediated by PHB, and also provided an indirect method for the binding of AHP-GNPs to 
cells. 
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Figure 3.12. Quantification of AHP-FITC binding to Caco-2 cells and the displacement of AHP-
GNPs.  
The Caco-2 cells were treated with AHP-FITC in the present of AHP-GNPs for 1hr at either 37
º
C (A) or 
4
º
C (B). 
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3.6. Intracellular uptake: Quantitative studies 
3.6.1. Cellular uptake of AHP-GNPs and AHP-QDs 
To assess the cellular uptake, cells were exposed to both unfunctionalized and AHP- 
functionalized QDs and GNPs to assess the cellular uptake. The cellular uptake was 
evaluated using ICP-OES. Cadmium and gold were detected in the cells treated with 
AHP- functionalized QDs and GNPs, No cadmium or gold detected from cells treated 
with unfunctionalized QDs or GNPs. This is shown in Figure 3.13. 
 
 
     
 
Figure 3. 13. The percentage of treated AHP-GNPs and AHP-QDs as quantified by ICP-OES. 
The cells were treated with GNPs, AHP-GNPs or QD625, AHP-QDs. The bar graph indicates cellular 
uptake of AHP-GNPs (A) and AHP-QDs (B), indicated by % treated dose. Asterisk (***) indicates 
statistical significance at p<0.0001 
A 
B 
*** 
*** 
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3.6.2. Cellular uptake of AHP-GA-GNPs 
To assess the cellular uptake, Caco-2 cells were exposed to both unfunctionalized GA-
GNPs, and AHP- functionalized GA-GNPs for 24hrs at 37
º
C 5 % CO2 incubator. The 
cellular uptake were analyzed using both ICP-MS and ICP-OES (Figure 3.14). Gold was 
detected in the cells treated with AHP- functionalized GA- GNPs. No gold was detected 
from the cells treated with unfunctionalized GA-GNPs.  The presence of gold in the cells 
indicate cellular uptake and binding of the AHP on the cell.  
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Figure 3.14. Quantification of cellular uptake for AHP-GA-GNPs and AHP-GNPS by ICP-OES.  
The cells were exposed to GNPs, AHP-GNPs or AHP-GA-GNPs for 24 hrs. Graph show concentration of 
gold (Au) present in each sample (A) and as % of treatment dose (B), as determined ICP-OES. Asterisk 
(***) indicates statistical significance at p<0.0001 
 
 
 
 
Chapter 3                                                                                                   Results: In vitro studies 
126 
 
3.7. Cell viability studies on Caco-2 cells 
3.7.1. Effects of GNPs, AHP and QDs on cell viability 
To determine the effects of GNPs and QDs on Caco-2 cells, the cells were treated with 
GNPs; AHP-GNPs or QD625; AHP-QDs for 24 hrs and cell viability were measured 
using the WST-1 assay. Figure 3.15, shows that, as the concentration of GNPs or AHP-
GNPs increases, there were moderate decrease in cellular growth as compared to 
untreated cells, same trends were observed as the cells treated with QDs or AHP-QDs, 
Figure 3.16.  
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Figure 3. 15. Graph showing % viability of Caco-2 cells treated with GNPs and AHP-GNPs.  
The Caco-2 cells were treated with increase concentration of either GNPs or AHP-GNPs for 24hrs. The cell 
viability was tested using WST-1 assay. Asterisk (***) indicates statistical significance at p<0.0001 
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Figure 3.16. Graph showing % viability of Caco-2 cells treated with QD625 and AHP-QDs.   
The Caco-2 cells were treated with increase concentration of either QD625 or AHP-QDs for 24hrs. The cell 
viability was tested using WST-1 assay. Asterisk (***) indicates statistical significance at p<0.0001 
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To determine whether the peptide has effects on cellular growth, Caco-2 cells were 
incubated with increasing concentrations of AHP for 24 hrs. The cell viability was 
measured using WST-1 assay. Figure 3.17 shows a moderate decrease in cell viability 
with increase in AHP concentration  
 
 
Figure 3. 17.  Graph showing % viability of Caco-2 cells treated with AHP, measured for 24 hrs.  
The Caco-2 cells were treated with increase concentration of either AHP for 24hrs. The cell viability was 
tested using WST-1 assay. The sample were not statistical significance at P<0.05. 
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3.7.2. Cell viability of GA and AHP-GA-GNPs  
The cell viability was performed following the methods reported by Maurya et al., 2011, 
with some modification. Briefly, to determine cell viability or cell proliferation of GA on 
Caco-2 cells, cells were incubated for 24 hrs and WST-1 was used for cell viability. It 
was observed that, exposure to the increased concentration of GA (0, 12.5, 25, 50 nM) for 
24hrs, Caco2 cell growth was inhibited in a dose-dependent manner as compared to 
control groups at 0 nM. This is indicated in Figure 3.18. The same trend was observed as 
Caco-2 cells treated with the increased concentration of AHP-GNPs-GA (0, 1, 2, 4 nM), 
as shown in Figure 3.19. The Caco-2 cell growth was not inhibited when exposed to the 
peptide (AHP) alone; this is shown in Figure 3.20. The results were performed in 
triplicate and they were statistically significant where P<0.05, as analysed by prism 5 
statistics package. 
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Figure 3. 18. Graph showing % viability of Caco-2 cells treated with various concentration of Gallic 
acid (GA).   
The Caco-2 cells were treated with increased concentration of GA for 24 (A) and 48 hrs (B) The cell 
viability was tested using WST-1 assay. Asterisk (***) indicates statistical significance at p<0.0001 
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Figure 3. 19. Graph showing % viability of Caco-2 cells treated with various concentrations of AHP-
GA-GNPs.  
The Caco-2 cells were treated with increased concentration of AHP-GA-GNPs for 24 (A) and 48 hrs (B) 
The cell viability was tested using WST-1 assay. Asterisk (***) indicates statistical significance at 
P<0.0001 
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Figure 3. 20. Graph showing % viability of Caco-2 cells treated with various concentration of AHP. 
The Caco-2 cells were treated with increased concentration of AHP for 24 (A) and 48 hrs (B) The cell 
viability was tested using WST-1 assay. The sample were not statistical significance at P<0.05. 
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3.8. Induction of apoptosis by GA and AHP-GA-GNPs 
3.8.1. APOPercentage 
TM
 assay 
To determine the apoptotic effects, cells were treated for 24 hrs with GA (25 nM), AHP-
GA-GNPs (2nM) and Cisplatin (10 µM) and induction of apoptosis was assessed using 
the APOPercentage 
TM
 assay. Staining with the APOPercentage 
TM 
dye was quantified 
using FACScan 
TM
 (Becton Dickson) instrument (Figure 3.21), the histograms for cells 
treated with GA, AHP-GA-GNPs and Cisplatin shift to the right due to increased binding 
of the APOPercentage 
TM 
dye, suggesting the induction of apoptosis in cells treated with 
GA, AHP-GA-GNPs and Cisplatin. The morphological change induced by GA and AHP-
GA-GNPs was also investigated using inverted light microscopy. Morphological 
examination showed the typical feature of cell death, cell detachment, cell shrinkage and 
rounding up of the cells (Figure 3.22.). The cells undergoing apoptosis are stained with 
APOPercentage 
TM 
dye as indicated in Figure 3.22.  
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Figure 3.21. The quantification of apoptosis in Caco-2 cells by flow cytometry.  
The cells were treated with Cisplatin (B), AHP-GA-GNPs (C) or GA (D), for 24 hrs. The cells were then 
stained with APOPercentage
TM
 dye and analyzed using flow cytometry. Histogram A, indicate the 
untreated cells. The shift of the cells distribution to the right into the second decade (M2) indicates the cells 
undergoing apoptosis that is an increase in fluorescence as indicated by %.  
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Figure 3.22. Morphological images in Caco-2 cells treated with GA, AHP-GA-GNPs and cisplatin.  
 
The cells were incubated for 24 hrs with either Cisplatin (10 µM), AHP-GA-GNPs (2 nM) or GA (25 nM). 
The cells were then stained with APOPercentage dye (1:120) dilution for 30 minutes and the cell 
morphology was observed under inverted light microscopy. The arrow on the image indicates the cells 
stained with APOPercentage dye which indicates marker of apoptosis. 
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3.8.2. Caspase 3 activation of GA and AHP-GA-GNPs 
To determine whether the GA, AHP-GA-GNPs activates caspase-3, cells were treated 
with GA or AHP-GA-GNPs or Cisplatin (as positive control) for 24 hrs and thereafter 
incubated with anti-active caspase-3 antibody. The cells were examined under the 
inverted light microscope for morphological changes and analyzed on FACScan 
TM
 
(Becton Dickson) instrument to determine caspase-3 activity. Negative control cells were 
used to set cells in the negative quadrant before all sample were acquired. Samples were 
acquired and analyzed using CELLQuest PRO software (BD Biosciences). The cells 
treated with cisplatin, GA and AGA-GNPs undergo apoptosis after 24 hrs as compared to 
untreated cells, as shown by activation of caspase-3 measured by the fluorescence of 
active caspase-3 FITC (Figure 3.23). 
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Figure 3.23. Quantification of the activation of Caspase 3 in Caco-2 cells by flow cytometry. 
Caco-2 cells were treated for 24 hrs with Cisplatin 10 µM (B), A-GA-GNPs 2 nM, (C) or GA 25 µM (D), 
stained with anti-active caspase-3 antibody and analysed by flow cytometry. Histogram A, indicate 
untreated cells.The shift of the cells distribution to the right into the second decade (M2) indicates the cells 
activating caspase- 3 that is an increase in fluorescence as indicated by %. 
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CHAPTER 4 
4. Results: In vivo studies 
4.1. Measurement of body weight, organs and adipose tissue mass 
To assess the difference between the body weight of low fat (LF) (lean) and high fat (HF) 
(obese) fed rats, the rats were weighed weekly during the obesity induction period. This 
was done to see if there will be changes in their body weight. It is shown in Figure 4.1 
and Figure 4.2, that the HF fed diet rats were heavier as compared to the LF group. The 
difference in groups were found to be statistically significant at p < 0.05, as analysed by 
Graph pad prism 5 statistical package.  
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Figure 4. 1. The body weights gain of LF and HF diet induced rats measured weekly.  
The rats (HF and LF group) were measured weekly. Asterisk (*) indicates statistical significance at p<0.05. 
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Figure 4. 2. The body weights gain of LF and HF diet induced rats measured at termination. 
The rats (HF and LF group) were measured at termination. HF group were heavier than the LF group. 
Asterisk (*) indicates statistical significance at p<0.05. 
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4.1.2. Tissues and organs weights 
To determine the weights of body tissues and organs, tissues were dissected and weighed 
at termination as indicated in Table 4.1. The adipose tissue weights including, inguinal or 
subcutaneous (SQ), epididymal (EPI), perirenal (PERI), retroperitoneal (RETRO) and 
mesenteric (MES) fat pads were found to be heavier and significantly increased in the HF 
group as compared to those in the LF group, as shown in Figure 4.3. The weights of 
these tissue in both groups were found to be statistically significant at p<0.05 as analysed 
by Graph pad prism 5 statistical package.  
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Table 4. 1.The average body and tissue weights isolated from LF and HF rats at termination 
Asterisk (***) indicates statistical significance at p<0.0001, (*) indicates statistical significance at p<0.05, 
NS - not statistically significant and    increase. Data is presented as Means ± SD/SE, n=20  
 
 LF HF 
BW 539.7 ± 15.9 701.2 ± 14.8 * 
SQ 15.3 ± 2.05  36.2 ± 2.12 *** 
EPI 8.72 ± 0.85 23.3 ± 1.09 *** 
MES 8.66 ± 0.92 18.4 ± 0.87 *** 
RETRO 6.33 ± 0.83 29.5 ± 0.74 *** 
PERI 2.05 ± 0.45 4.25 ± 0.05 *** 
Kidneys 3.10 ± 0.09 3.04 ± 0.13 NS 
Lungs 1.76 ± 0.07 1.99 ± 0.16  ,NS 
Liver 15.5 ± 0.84 15.8 ± 0.61 NS 
Spleen 1.03 ± 0.06 0.96 ± 0.05 NS 
Testes 3.77 ± 0.05 3.78 ± 0.07 NS 
Heart 1.44 ± 0.06 1.48 ± 0.05 NS 
Brain 2.09 ± 0.04 2.13 ± 0.02 NS 
Stomach 2.31 ± 0.08 2.79 ± 0.47  ,NS 
Pancreas 2.22 ± 0.24 2.58 ± 0.14  ,NS 
Adrenal 0.05 ± 0.004 0.06 ± 0.005 NS 
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Figure 4. 3. The average weights of various adipose tissue depots. 
The perirenal (PERI), epidydimal (EPI) subcutaneous (SQ), mesenteric (MES) and retroperitoneal 
(RETRO) weights isolated from LF and HF rats, measured at termination.   Asterisk (***) indicates 
statistical significance at p<0.0001 
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The weights of adrenals, pancreas, stomach and lungs were slightly heavier, in the HF 
group as compared to those in the LF group but statistically they were not significant at 
P<0.05 while the weight of the spleen, brain, testes, heart, liver and kidneys were the 
same in both groups, however they were not statistically significant. Between the weights 
of the pancreas a significance different was observed at p<0.05. The average tissue 
weights of LF and HF groups are indicated in Table 4.1 and Figure 4.4 & 4.5. 
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Figure 4. 4. The average weights of spleen, adrenal, pancreas, stomach and lungs isolated from LF 
and HF rats, measured at termination. 
Asterisk (**) indicates statistical significance at p<0.0061 
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Figure 4. 5. The average weights of brain, testes, heart, liver and kidneys isolated from LF and HF 
rats at termination. 
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4.2. Adiposity index 
 
To determine what percentage weight each tissue contributed to the final body weight, 
the weight of each tissue was divided by the final body weight at termination and 
multiplied by 100. The adiposity index was then determined as the percentage of the sum 
of weights of all WAT in relation to the total body weight. This was expressed as 
percentage adiposity index as indicated in Figure 4.6. The adiposity index was found to 
be higher for the HF group with 15.98 ± 0.39 as compared to the LF group with 7.5 ± 
0.67 as indicated in Figure 4.6.  
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Figure 4. 6. The total percentage (%) body weight index in both LF and HF groups at termination. 
 Asterisk (***) indicates statistical significance at p<0.0001 
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4.3. Biodistribution studies of QDs after intravenous injection 
 4.3.1. Ex vivo imaging of QDs using IVIS® Lumina XR 
To assess the biodistribution and localization of QDs in vivo, lean and obese rats (Figure 
4.1) were intravenously injected with unfunctionalized and AHP-functionalized QDs. 
The organs and tissues were dissected out and imaged using IVIS® Lumina XR. No 
fluorescence was observed in organs and WATs from PBS-treated rats (control group). 
The unfunctionalized QDs accumulated in the liver, testes, kidney and brain, but rarely 
distributed in WATs. In contrast, the AHP-functionalized QDs accumulates mostly in the 
WAT (mesenteric, inguinal, epidydimal and retroperoteneal) but did not accumulated in 
the organs. The intense yellow fluorescence was observed in liver, testes, kidney and 
brain, but accumulated mainly in WATs of the AHP functionalized QDs as indicated in 
Figure 4.7. 
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Figure 4.7. Photographs and fluorescence images of isolated organs of rats intravenously injected 
with unfunctionalized and AHP-functionalised QDs.  
Biodistribution of QDs was determined 24 hrs after intravenous injection. Organs were dissected after 24 
hrs, and imaged under IVIS® Lumina XR, using DsRed filter (Excitation wavelength ranges between 430-
745 nm and Emission, 580-700nm) and results analysed using IVIS living image software. 
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4.3.2. The quantitative analysis of QDs and GNPs using ICP-OES  
 
To quantitatively assess the concentrations of QDs and GNPs in vivo, lean and obese rats 
were injected intravenously with unfunctionalized and AHP-functionalised QDs and 
GNPs, and organs and tissues were analyzed by ICP-OES. As shown in Figure 4.8, high 
concentrations of Cd were measured mainly in the liver, lungs, spleen, kidney and testes 
from rats injected with unfunctionalized QDs. Low concentrations of Cd were observed 
in WATs, except retroperitoneal WAT. In contrast, low levels of Cd were measured in 
liver, lungs, spleen, kidney and testes from rats injected with AHP-functionalised QDs. 
High concentrations of Cd were measured in WAT. The same trend was observed in the 
measurement of gold in organs of rats injected with unfunctionalized and AHP-
functionalized GNPs (Figure 4.9). 
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Figure 4. 8. Percentage injected dose of cadmium, in selected organs to determine biodistribution of QDs.  
Rats were injected intravenously with PBS, unfunctionalized and AHP-functionalized QDs. Organs and tissues were dissected after 24 hrs. 
Quantification of Cadmium (Cd) in various organs was determined by ICP-OES.  
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Figure 4. 9. Percentage injected dose of gold in selected organs, to determine biodistribution of GNPs. 
Rats were injected intravenously with PBS, unfunctionalized and AHP-functionalized GNPs. Organs and tissues were dissected after 24 hrs. 
Quantification of gold (Au) in various organs was measured by ICP-OES.
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4.4. Measurement of Free fatty acid (NEFA), Insulin and glucose level 
 
The serum samples from both lean and obese rats were analysed to determine the 
concentration of free fatty acid, insulin and glucose. It is shown in Figure (4.10; 4.11; 
4.12) and Table 4.1 that the higher concentration of NEFA, insulin and glucose were 
observed in the serum obtained from obese (HF) rats as compared to the lean (LF) rats. 
The results were statistically significant at p<0.05. 
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Figure 4. 10. Measurement of free fatty acid levels in the serum samples of both lean (LF) and obese 
(HF) groups.   
Asterisk (***) indicates statistical significance at p<0.0001 
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Figure 4. 11. Measurement of insulin levels in the serum samples of both lean (LF) and obese (HF) 
groups.  
Asterisk (***) indicates statistical significance at p<0.0001 
 
 
 
 
 
 
 
 
 
 
 
                 Chapter 4                                                                                                  Results: In vivo studies 
 
158 
 
 
LF H
F
0
20
40
60
G
lu
c
o
s
e
 (
u
g
/u
l)
**
 
Figure 4. 12. Measurement of glucose concentration in serum samples of lean (LF) and obese (HF) 
groups.  
Asterisk (**) indicates statistical significance at p<0.0014 
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Table 4. 2. The concentration of serum insulin, glucose and NEFA.  
This table shows the concentration of insulin, glucose and NEFA obtained from serum of lean 
(LF) and obese (HF) Wistar rats. 
 
 BW (g) Insulin conc.(µg/L) Glucose conc.(µg/µL) NEFA conc.(mg/dL) 
 
 
LF 
 
 
539.73 
 
 
0.69 
         
         
            40.8 
 
 
0.185 
HF 701.23   0.811             48.0 0.283 
 
Abbreviations: LF (Low fat), HF (High fat), BW (Body weights), NEFA (Non-esterified fatty acid), 
Conc (concentration) 
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CHAPTER 5 
5.1. General discussion 
 
The study focused on the development of nanotechnology based drug delivery systems 
(GNPs) and imaging agents (QDs) to the white adipose tissue vasculature using obese 
male Wistar rats. In 2004, Kolonin et al, discovered a synthetic peptide motif (sequence 
CKGGRAKDC), which was found to be a vascular targeting peptide that homes to the 
white fat vasculature. Of our interest, we then named the peptide an Adipose Homing 
Peptide “shorten” AHP. PHB was found to be a target for AHP, which is now known as a 
vascular marker of adipose tissue. For the advancement of the study, the GNPs and QDs 
were functionalized with AHP to specifically target the white adipose tissue vasculature. 
Functionalization of the nanoparticles was confirmed using agarose gel electrophoresis 
and UV-vis spectroscopy. UV-vis spectroscopy showed a change in absorbance but not in 
the absorption peak, as indicated in Figure 3.1 and 3.2. These results correlate with other 
studies, showing that functionalized NPs migrate slower on agarose gel than the 
unfunctionalized NPs. This was attributable to surface modification (Kumar et al., 2012).  
 
However, PL characterisation of QD625 and AHP-QDs did not change the emission 
spectrum of the QDs (Figure 3.4). A study by (Franchello et al.) also showed that 
functionalization of the NPs does not change the PL characteristics of QD625 (Franchello 
et al., 2013). This study is therefore in agreement with the work done by Franchello and 
colleaques.  
  
 
 
 
 
Chapter 5                                                                               General discussion, conclusion and future work 
161 
 
 
In addition, several studies indicated that various NPs functionalized with different 
biomolecules can be used in nanotechnology, due to their versatility, ease in chemical 
synthesis, less toxicity and biocompatibility (McNeil, 2005; Lira et al., 2012). 
Furthermore, range of these NPs are used as imaging and drug-delivery systems and can 
be formulated from diverse materials with unique architectures to serve as possible drug-
delivery vehicles to treat variety of diseases (Atlanta, 2005; Lira et al., 2012; Parveen et 
al., 2012).  
 
To confirm PHB as a target for AHP, GNPs and QDs were functionalized with AHP and 
the binding specificity was tested in PHB expressing cells, the MCF-7 and Caco-2 cells. 
The expression of PHB in these cell lines was described in the literature (Rastogi et al., 
2006; Sharma and Qadri, 2004). Immunofluorescence staining was performed on MCF-7 
cells to confirm the expression of PHB and to investigate the localization of PHB. The 
anti-PHB antibody was confirmed in the mitochondrion. This is shown in Figure 3.5. 
The localization of PHB in the nucleus was also confirmed using anti-PHB antibody and 
DAPI as indicated in Figure 3.6. 
 
The study done by Kolonin et al., (2004), showed that AHP specifically targets adipose 
tissue vasculature and binds to PHB expressed on endothelial cells. Figure 3.7 and 3.8, 
confirmed the binding of AHP-QDs to MCF-7 and Caco-2 cells, as determined by 
fluorescence microscopy. Cells that do not express PHB (CHO, KMST-6) did not show 
any binding of AHP-QDs (Figure 3.9).   
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The binding and uptake of AHP-QDs was studied in ECs generated from lean and obese 
Wistar rats, by quantifying the concentration of cadmium (Cd) in the cells, following 
exposure of the cells to AHP-QDs and QD625. The concentration of Cd in ECs isolated 
from lean rats was much lower compared to ECs isolated from obese rats (Figure 3.11). 
The Cd concentration for cell treated with QD625 was very low for ECs produced from 
both lean and obese rats. 
 
Taken together, these data suggest that the binding of AHP was receptor-mediated and 
specific to a receptor that is expressed in ECs from obese WAT. We speculate that this 
could be due to increased PHB expression on the cell surface of ECs from obese rats as 
indicated by Hossen et al., 2010.  Although it has been reported that PHB is an inner 
mitochondrial protein that is present in all cells and nuclear expression in some types of 
cells, it is also expressed on the plasma membrane of vascular endothelial cells in adipose 
tissue.  
 
To determine the specificity of AHP binding Caco-2 cells (PHB expressing cells) were 
incubated with AHP-FITC at 4 and 37
o
C, in the presence or absence of AHP-GNPs as 
competitor to AHP-FITC. Incubation at 4°C prevented the binding and uptake of AHP-
FITC by Caco-2 cells (Figure 3.12(A)). Also, incubation of cells with AHP-FITC in the 
presence of AHP-GNPs reduced the uptake of AHP-FITC by Caco-2. In contrast, cells 
incubated at 37°C (Figure 3.12(B)) showed higher binding and uptake of AHP-FITC by 
Caco2 cells. This further suggests that the binding of AHP was receptor mediated. 
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To quantitatively assess the cellular uptake, Caco-2 cells were exposed to QD625; AHP-
QDs, GNPs; AHP-GNPs or GA; AHP-GA-GNPs. Intracellular concentration of Cd and 
gold (Au) were detected in the cells using ICP-OES (Figure 3.13 and 3.14). Very low 
level of Cd and Au were detected in cells treated with unfunctionalized QDs (QD625) 
and GNPs. 
 
This indicated that the particles are unable to bind or to be taken up by the PHB 
expressing cells, due to absence of AHP on the particles. This is in line with the work 
done by Kumar and colleaques (2012), where the functionalized particles were taken up 
by the cells as compared to unfunctionalized NPs. Neither AHP-QDs or AHP-GNPs nor 
GNPs and QDs were toxic to the cells, as shown in Figure 3.15 and 3.16. This correlates 
with the published studies (Choi and Frangioni, (2010); Kima et al., 2012), that most of 
the functionalized and PEGylated NPs have little effect on the cellular viability. In 
contrast GA, AHP-GA-GNPs reduced cellular viability in Caco-2 cells at 24 and 48 hrs 
treatment, (Figure 3.18 and 3.19) and induced apoptosis through activation of Caspase-
3, as seen by the increase or shift in the fluorescence of Caspase-3 FITC, compared to 
untreated cells,  (Figure 3.21 and 3.23).  
 
In order to determine whether the observed in vitro effects of AHP are applicable in vivo, 
the male Wistar rats were used. These rats were either obese induced (HF) or standard 
chow fed rats (LF). It was observed that the obese (HF) rats were much heavier than the 
lean (LF) rats (Figure 4.1 and 4.2). The adipose tissue weights were also heavier and 
significantly increased in the HF group compared to those in the LF group. The adiposity 
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index was higher for the HF group as compared to the LF group (Figure 4.6). This is in 
line with published literature where the fat percentage on HF fed rats is higher than in the 
LF fed rats (Shanmugam et al., 2009; Jeyakumar et al., 2009).The biodistribution and 
localization of QDs in vivo was assessed in lean and obese rats. No fluorescence was 
observed in organs and WATs from control group (PBS-treated rats), (Figure 4.7). The 
QDs accumulated in the liver, testes, kidney and brain, but barely distributed in WATs. In 
contrast, the AHP- QDs accumulates mostly in the WAT but did not accumulate in other 
organs as indicated in Figure 4.7. 
 
Quantitatively high concentrations of Cd was measured mainly in the liver, lungs, spleen, 
kidney and testes from rats treated with unfunctionalized QDs. Low concentrations of Cd 
were observed in WATs, except retroperitoneal WAT. In contrast, low levels of Cd were 
measured mainly in liver, lungs, spleen, kidney and testes from rats treated with AHP-
QDs. High concentrations of Cd were measured in WAT. The same trend was observed 
in the measurement of gold in organs of rats injected with GNPs and AHP- GNPs 
(Figure 4.8 and 4.9). This data correlate with most of the studies reported in the 
literature (Sonavane et al., 2008; Lasagna-Reeves et al., 2010; Wang et al, 2010; Morais 
et al., 2012) where most of the NPs accumulate mostly in the liver, lungs, kidneys and 
spleen. Lasagna-Reeves and colleagues, (2010) and Wang and colleagues, (2010) showed 
that the NPs are taken up by Kupffer cells in the liver, and that the liver is unable to clear 
exogenous NPs easily. Also and the increasing NPs in the spleen might originate from 
NPs excreted from lung and kidney since the Kidney is the most important organ for 
excretion of waste and some metabolites (Zhang et al., 2012).  
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This is because these organs of the reticuloendothelial systems (RES), [liver, spleen and 
lung] internalize NPs through the action of macrophages and lymphocytes. Taken 
together, these results indicate that AHP-functionalized NPs accumulate preferentially in 
WATs, suggesting that AHP targets PHB on the WAT vasculature in vivo. This 
confirmed that PHB is selectively expressed at high levels on the white adipose tissue 
vasculature. This is supported by the work done by Kolonin et al., (2004) and Hossen et 
al., (2010).  
 
This study showed that obese rats had higher serum concentration of NEFA, insulin and 
glucose compared to the lean rats, (Figure 4.10 - 4.12). An increase in NEFA plasma 
concentration is linked with insulin resistance, which plays a role in the development of 
diseases such as diabetes mellitus, (Karpe et al., 2011). Other studies reported that 
circulating NEFA stimulate β-cell insulin secretion which eventually contributes to the 
development of insulin resistance in both skeletal muscle and liver, classical features in 
obese individuals (Mohamed-Ali et al., 1998). In this study, the increase in glucose level 
in the presence of high insulin level indicate that the obese rats were insulin resistant, that 
insulin action in the disposal of glucose was limited in insulin sensitive tissues.  Elevated 
NEFA concentrations in obesity could result from the process of fatty acid mobilization 
from adipose tissue through lipolysis. This then leads to a vicious cycle increasing insulin 
resistance (Karpe et al., 2011). 
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5.2. Conclusions 
 
NPs suffer from the problem of uptake by the RES (Lasagna-Reeves et al., 2010; Choi 
and Frangioni, 2010; Liu et al., 2010; Zhang et al., 2012). In addition to NPs size, surface 
charge plays a key role in RES uptake. This is because the filtration barrier is covered 
with a layer of polyanionic glycoproteins that repel most large anions, (Choi and 
Frangioni, 2010). However, surface charge and hydrophobicity promote adsorption or 
opsonization by serum proteins present in the blood, which bind to foreign particles and 
increase recognition by phagocytic cells, (Choi and Frangioni, 2010; Liu et al., 2010). 
The binding of these proteins result in an effective increase in hydrodynamic density and 
can prevent renal clearance of NPs. Therefore, surface modification of NPs using 
hydrophilic biologically inert, neutral polymers such as PEG will slow the rate of 
clearance from the blood and retention in the RES (Choi and Frangioni, 2010; Zhang et 
al., 2012). 
 
Therefore, the development of nanotechnology based drug delivery and imaging agents to 
the WAT vasculature was successful. Figure 5.1 illustrate the potential mechanism by 
which targeted drug loaded nanoparticles can be delivered to the cells and induce 
apoptosis. This study shows successful selective delivery of AHP-QDs and AHP-GNPs 
to WAT vasculature in vivo. It also demonstrates that GA and AHP-GA-GNPs induced 
cell viability and apoptosis in vitro. Unfortunately the in vivo applications of  GA and 
AHP-GA-GNPs was not done due to time constraits. Moreover, while this study was 
ongoing. Hossen et al., (2012), published the work on vascular-targeted nanotherapy for 
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obesity using liposomes. Hossen‟s work support the data obtained in this study and the 
specificity of prohibitin as a target for the WAT. The success in targeting WAT 
vasculature has reached the clinical trial stage using proapoptotic peptide D(KLAKLAK)2 
(Kolonin et al., 2004; Hossen et al., 2012). On the other hand the use of D(KLAKLAK)2 
might be expensive compared to GA. Therefore there is a need to screen different anti-
obesity conjugated nanoparticles. This study represents a potential approach for targeted 
drug delivery systems to the adipose tissue and also improves the body of knowledge in 
obesity treatment. 
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5.3. Future work 
 
This study showed a plausible mechanism for treatment of obesity, and a promise of the 
drug-loaded AHP functionalized GNPs (GA-AHP-GNPs) in vivo. This construct needs to 
be tested in the near future for its anticipated effects in the reduction of body weight of 
obese rodents. Much of the forecasted promise of nanotechnology in medicine is 
premised around development of smart technologies, such as theranostic platforms that 
can target, diagnose and administer treatment to different diseased areas in the body. 
Therefore, this study forms the basis for a theranostic platform on which other 
proapototic agents or drugs could be screened for treatment of obesity. For example, 
antiobesity drugs that have been removed from the market could be revived by attaching 
them to GNPs functionalized with AHP.  
 
Although this study demonstrated the use of biocompatible nanoparticles, both GNPs and 
QDs, their potential toxicity remains a concern. The literature is flooded with references 
indicating GNPs to be non-toxic, and cadmium-based QDs to be toxic. However, the 
durations of experiments used could not answer whether persistence in the body may 
produce longer-term toxicities. Therefore, it will be important to study whether longterm 
exposure to the nanoparticles used in this study have any toxic effects to normal tissues 
over a long period of time. The use of other less toxic QDs for imaging purposes must be 
considered in the future to reduced exposure toxic nanoparticles. Moreover, future studies 
must be setup to determine whether the route of administration of nanoparticles can affect 
the therapeutic efficancy of the drug-loaded nanoparticles.  
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And finally, the advancement of biomarker discoveries in obesity and its associated 
chronic diseases will be key to the development of novel theranostics for obesity 
treatment. These biomarkers will render new targets for the diseased tissues and reduce 
bystander toxicity effects of nanoparticles. Continued development and combination of 
these applications will lead to revolutionary advances in the treatment of obesity, and 
those foreseen in nanomedicine. 
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Figure 5.1. The possible mechanism of targeted drug delivery to the endothelial cells for obesity 
treatment. 
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